<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="pmc-domain-id">3416</journal-id><journal-id journal-id-type="pmc-domain">molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8747035</article-id><article-id pub-id-type="pmcid-ver">PMC8747035.1</article-id><article-id pub-id-type="pmcaid">8747035</article-id><article-id pub-id-type="pmcaiid">8747035</article-id><article-id pub-id-type="pmid">35011550</article-id><article-id pub-id-type="doi">10.3390/molecules27010321</article-id><article-id pub-id-type="publisher-id">molecules-27-00321</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Design, Synthesis, and Biological Evaluation of 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidines as Microtubule Targeting Agents</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Islam</surname><given-names initials="F">Farhana</given-names></name><xref rid="af1-molecules-27-00321" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Doshi</surname><given-names initials="A">Arpit</given-names></name><xref rid="af1-molecules-27-00321" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Robles</surname><given-names initials="AJ">Andrew J.</given-names></name><xref rid="af2-molecules-27-00321" ref-type="aff">2</xref><xref rid="af3-molecules-27-00321" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Quadery</surname><given-names initials="TM">Tasdique M.</given-names></name><xref rid="af1-molecules-27-00321" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xin</given-names></name><xref rid="af1-molecules-27-00321" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="X">Xilin</given-names></name><xref rid="af1-molecules-27-00321" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hamel</surname><given-names initials="E">Ernest</given-names></name><xref rid="af4-molecules-27-00321" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8575-2516</contrib-id><name name-style="western"><surname>Mooberry</surname><given-names initials="SL">Susan L.</given-names></name><xref rid="af2-molecules-27-00321" ref-type="aff">2</xref><xref rid="af3-molecules-27-00321" ref-type="aff">3</xref><xref rid="c1-molecules-27-00321" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gangjee</surname><given-names initials="A">Aleem</given-names></name><xref rid="af1-molecules-27-00321" ref-type="aff">1</xref><xref rid="c1-molecules-27-00321" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Micale</surname><given-names initials="N">Nicola</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-27-00321"><label>1</label>Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA; <email>islamf@duq.edu</email> (F.I.); <email>doshia@duq.edu</email> (A.D.); <email>quaderyt@duq.edu</email> (T.M.Q.); <email>zhangx@duq.edu</email> (X.Z.); <email>zhoux@duq.edu</email> (X.Z.)</aff><aff id="af2-molecules-27-00321"><label>2</label>Department of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA; <email>roblesa3@uthscsa.edu</email></aff><aff id="af3-molecules-27-00321"><label>3</label>Mays Cancer Center, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA</aff><aff id="af4-molecules-27-00321"><label>4</label>Molecular Pharmacology Branch, Developmental Therapeutics Program, Frederick National Laboratory for Cancer Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA; <email>hamele@dc37a.nci.nih.gov</email></aff><author-notes><corresp id="c1-molecules-27-00321"><label>*</label>Correspondence: <email>mooberry@uthscsa.edu</email> (S.L.M.); <email>gangjee@duq.edu</email> (A.G.)</corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>1</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2022</year></pub-date><volume>27</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">398108</issue-id><elocation-id>321</elocation-id><history><date date-type="received"><day>07</day><month>10</month><year>2021</year></date><date date-type="accepted"><day>22</day><month>12</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>01</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>11</day><month>01</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-19 18:25:17.190"><day>19</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="molecules-27-00321.pdf"/><abstract><p>A series of eleven 4-substituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidines were designed and synthesized and their biological activities were evaluated. Synthesis involved the Gewald reaction to synthesize ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate ring, and S<sub>N</sub>Ar reactions. Compound <bold>4</bold> was 1.6- and ~7-fold more potent than the lead compound <bold>1</bold> in cell proliferation and microtubule depolymerization assays, respectively. Compounds <bold>4</bold>, <bold>5</bold> and <bold>7</bold> showed the most potent antiproliferative effects (IC<sub>50</sub> values &lt; 40 nM), while compounds <bold>6</bold>, <bold>8</bold>, <bold>10</bold>, <bold>12</bold> and <bold>13</bold> had lower antiproliferative potencies (IC<sub>50</sub> values of 53&#8211;125 nM). Additionally, compounds <bold>4</bold>&#8211;<bold>8</bold>, <bold>10</bold> and <bold>12</bold>&#8211;<bold>13</bold> circumvented Pgp and <italic toggle="yes">&#946;</italic>III-tubulin mediated drug resistance, mechanisms that diminish the clinical efficacy of paclitaxel (PTX). In the NCI-60 cell line panel, compound <bold>4</bold> exhibited an average GI<sub>50</sub> of ~10 nM in the 40 most sensitive cell lines. Compound <bold>4</bold> demonstrated statistically significant antitumor effects in a murine MDA-MB-435 xenograft model.</p></abstract><kwd-group><kwd>microtubules</kwd><kwd>colchicine site</kwd><kwd>microtubule targeting agents</kwd><kwd>Gewald reaction</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-27-00321"><title>1. Introduction</title><p>Microtubules have long been recognized as effective targets for the treatment of many human malignancies [<xref rid="B1-molecules-27-00321" ref-type="bibr">1</xref>,<xref rid="B2-molecules-27-00321" ref-type="bibr">2</xref>]. Microtubules are involved in a variety of cellular functions including mitosis, motility, intracellular transport, trafficking and organization, including positioning of organelles [<xref rid="B1-molecules-27-00321" ref-type="bibr">1</xref>,<xref rid="B3-molecules-27-00321" ref-type="bibr">3</xref>,<xref rid="B4-molecules-27-00321" ref-type="bibr">4</xref>]. Molecules binding to tubulin and interrupting tubulin dynamics are recognized as microtubule targeting agents (MTAs), and they have been used clinically as single agents or in combinatorial regimens for the effective treatment of leukemia, lymphoma and various solid tumors [<xref rid="B2-molecules-27-00321" ref-type="bibr">2</xref>,<xref rid="B3-molecules-27-00321" ref-type="bibr">3</xref>,<xref rid="B5-molecules-27-00321" ref-type="bibr">5</xref>]. MTAs are a highly diverse class of cytotoxic agents that include a variety of different chemical scaffolds (<xref rid="molecules-27-00321-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B2-molecules-27-00321" ref-type="bibr">2</xref>,<xref rid="B3-molecules-27-00321" ref-type="bibr">3</xref>,<xref rid="B6-molecules-27-00321" ref-type="bibr">6</xref>].</p><p>MTAs can be classified into two major groups: (1) microtubule destabilizers that initiate microtubule depolymerization; and (2) microtubule stabilizers that promote the polymerization of tubulin into microtubules [<xref rid="B1-molecules-27-00321" ref-type="bibr">1</xref>,<xref rid="B2-molecules-27-00321" ref-type="bibr">2</xref>]. Additionally, MTAs are further divided into seven groups based on their binding sites [<xref rid="B6-molecules-27-00321" ref-type="bibr">6</xref>,<xref rid="B7-molecules-27-00321" ref-type="bibr">7</xref>]. Two binding sites on tubulin/microtubules have been identified for microtubule stabilizers [<xref rid="B8-molecules-27-00321" ref-type="bibr">8</xref>]. First, the taxane site is located on the interior of the microtubule, and all clinically approved microtubule stabilizers, including paclitaxel (<xref rid="molecules-27-00321-f001" ref-type="fig">Figure 1</xref>), docetaxel (<xref rid="molecules-27-00321-f001" ref-type="fig">Figure 1</xref>), cabazitaxel and ixabepilone, bind to this site [<xref rid="B8-molecules-27-00321" ref-type="bibr">8</xref>]. The taccalonolides (<xref rid="molecules-27-00321-f001" ref-type="fig">Figure 1</xref>), zampanolide and cyclostreptin are compounds that bind covalently within the taxane site, but to date have not been evaluated clinically [<xref rid="B8-molecules-27-00321" ref-type="bibr">8</xref>,<xref rid="B9-molecules-27-00321" ref-type="bibr">9</xref>,<xref rid="B10-molecules-27-00321" ref-type="bibr">10</xref>]. The second stabilizer site is the laulimalide/peloruside site, which is located on the exterior of the microtubule and named for the natural products that bind to this site [<xref rid="B8-molecules-27-00321" ref-type="bibr">8</xref>]. The clinical development of compounds binding to this site has been limited by a lack of in vivo efficacy for laulimalide [<xref rid="B11-molecules-27-00321" ref-type="bibr">11</xref>] and supply challenges for peloruside A [<xref rid="B12-molecules-27-00321" ref-type="bibr">12</xref>]. In the class of microtubule destabilizers, five sites have been identified: the vinca site, the colchicine site (CS), the maytansine site, the pironetin site [<xref rid="B6-molecules-27-00321" ref-type="bibr">6</xref>], and more recently the gatorbulin site (gatorbulin-1, <xref rid="molecules-27-00321-f001" ref-type="fig">Figure 1</xref>) defined by the cyclic peptide of the same name [<xref rid="B7-molecules-27-00321" ref-type="bibr">7</xref>]. The vinca alkaloids vinblastine, vincristine, vindesine, and vinorelbine, as well as other structurally unique/unrelated compounds, including eribulin (<xref rid="molecules-27-00321-f001" ref-type="fig">Figure 1</xref>), bind within the vinca site, which is located at the interdimer interface between two tubulin heterodimers in a protofilament [<xref rid="B6-molecules-27-00321" ref-type="bibr">6</xref>]. The colchicine binding site is located on <italic toggle="yes">&#946;</italic>-tubulin at the intradimer interface of the <italic toggle="yes">&#945;&#946;</italic>-tubulin heterodimer [<xref rid="B6-molecules-27-00321" ref-type="bibr">6</xref>]. The maytansine site is also on <italic toggle="yes">&#946;</italic>-tubulin, in close proximity but nonoverlapping with the vinca site [<xref rid="B13-molecules-27-00321" ref-type="bibr">13</xref>]. The gatorbulin site is located at the intradimer interface of tubulin similarly to the vinca alkaloids, but binding within this site is differentiated by extensive contacts with <italic toggle="yes">&#945;</italic>-tubulin [<xref rid="B7-molecules-27-00321" ref-type="bibr">7</xref>]. The pironetin site is the only MTA localized exclusively on <italic toggle="yes">&#945;</italic>-tubulin [<xref rid="B14-molecules-27-00321" ref-type="bibr">14</xref>].</p><p>While the clinically useful vinca alkaloids vinblastine and vincristine were approved decades ago, new MTAs have been approved more recently for clinical use. Eribulin (<xref rid="molecules-27-00321-f001" ref-type="fig">Figure 1</xref>), a simplified synthetic analogue of the natural product halichondrin B, is a microtubule depolymerizer that has unique properties [<xref rid="B5-molecules-27-00321" ref-type="bibr">5</xref>,<xref rid="B15-molecules-27-00321" ref-type="bibr">15</xref>] and significant utility in the treatment of advanced breast cancer [<xref rid="B15-molecules-27-00321" ref-type="bibr">15</xref>]. The dolastatin 10 analogue monomethyl auristatin E and maytansine (<xref rid="molecules-27-00321-f001" ref-type="fig">Figure 1</xref>) analogues are employed as the cytotoxic payloads of antibody-drug conjugates (ADCs) that have found clinical utility [<xref rid="B16-molecules-27-00321" ref-type="bibr">16</xref>]. These unconjugated MTAs were too toxic for systemic administration, but their antibody-directed delivery to cancers was designed to reduce off-target toxicities [<xref rid="B16-molecules-27-00321" ref-type="bibr">16</xref>]. Continuing challenges with clinically approved MTAs, including the taxanes and vinca alkaloids, are the incidence of dose-limiting side effects and limited efficacy due to multidrug resistance [<xref rid="B17-molecules-27-00321" ref-type="bibr">17</xref>]. Cancer cells and patients demonstrate resistance to clinically used agents as a result of the expression of the drug efflux pump P-glycoprotein (Pgp) and the <italic toggle="yes">&#946;</italic>III-tubulin isotype [<xref rid="B2-molecules-27-00321" ref-type="bibr">2</xref>,<xref rid="B18-molecules-27-00321" ref-type="bibr">18</xref>,<xref rid="B19-molecules-27-00321" ref-type="bibr">19</xref>], leading to efforts to identify new MTAs that can overcome these mechanisms of drug resistance.</p><p>CS inhibitors, including derivatives of combretastatin A-4 (CA-4, <xref rid="molecules-27-00321-f001" ref-type="fig">Figure 1</xref>), have been extensively studied, and several have been evaluated in clinical trials, including combretastatin A-4 phosphate (CA-4P/fosbretabulin), the combretastatin CA-1P prodrug (OXi4503), 2-methoxyestradiol, AVE8062, CKD-516, BNC105P, ABT-751, CYT-997, ZD6126, plinabulin (NPI-2358) and MN-029 [<xref rid="B20-molecules-27-00321" ref-type="bibr">20</xref>,<xref rid="B21-molecules-27-00321" ref-type="bibr">21</xref>,<xref rid="B22-molecules-27-00321" ref-type="bibr">22</xref>]. Colchicine itself is approved for the treatment of gout but is not employed as an anticancer agent due to toxic side effects at the doses necessary for efficacy [<xref rid="B23-molecules-27-00321" ref-type="bibr">23</xref>]. However, other CS agents have exhibited promising potential as anticancer candidates [<xref rid="B20-molecules-27-00321" ref-type="bibr">20</xref>,<xref rid="B21-molecules-27-00321" ref-type="bibr">21</xref>,<xref rid="B22-molecules-27-00321" ref-type="bibr">22</xref>]. Many compounds that interact with the CS are able to overcome multiple mechanisms of drug resistance [<xref rid="B24-molecules-27-00321" ref-type="bibr">24</xref>]. This suggests that the development of MTAs targeting the CS has the potential to overcome limitations associated with existing drugs and perhaps improve clinical outcomes. This has been challenging, however, and to date no CS agent has received FDA approval for anticancer indications [<xref rid="B22-molecules-27-00321" ref-type="bibr">22</xref>]. There is an urgent need to develop new tubulin inhibitors with fewer side effects and good oral bioavailability that are less prone to clinically relevant drug resistance mechanisms.</p></sec><sec sec-type="results" id="sec2-molecules-27-00321"><title>2. Results and Discussion</title><sec id="sec2dot1-molecules-27-00321"><title>2.1. Rationale</title><p>We previously reported [<xref rid="B25-molecules-27-00321" ref-type="bibr">25</xref>,<xref rid="B26-molecules-27-00321" ref-type="bibr">26</xref>] N4-substituted-pyrimido[4,5-b]indole-4-amines (<bold>1</bold>&#8211;<bold>3</bold>) (<xref rid="molecules-27-00321-f002" ref-type="fig">Figure 2</xref>) with potent microtubule depolymerization activity, with EC<sub>50</sub> values of 130, 1100 and 1200 nM for the lead compounds <bold>1</bold>, <bold>2</bold> and <bold>3</bold>, respectively. In MDA-MB-435 human cancer cells, the IC<sub>50</sub> values for antiproliferative effects for compounds <bold>1</bold>, <bold>2</bold> and <bold>3</bold> were 14.7, 89.1 and 130 nM, respectively. This study exploits four medicinal chemistry strategies for the design of potent MTAs based on the lead compounds <bold>1</bold>&#8211;<bold>3</bold>. The strategies are (1) isosteric replacement; (2) decrease numbers of sp2 bonds; (3) variation of substitutions at the 2-position; and (4) conformational restriction.
<list list-type="simple"><list-item><label>(1)</label><p>Isosteric replacement: To explore the activities of compounds with the 4,5,6,7-tetrahydrobenzo thiophene scaffold on both inhibition of cancer cell proliferation and microtubule depolymerization, we carried out the isosteric replacement of the scaffold -NH- of the lead compounds <bold>1</bold>&#8211;<bold>3</bold> by sulfur (-S-) to afford target compounds <bold>4</bold>&#8211;<bold>14</bold> (<xref rid="molecules-27-00321-t001" ref-type="table">Table 1</xref>). Isosteric replacement of -NH with (-S-) has literature precedence in improving antiproliferative and microtubule depolymerizing activities [<xref rid="B27-molecules-27-00321" ref-type="bibr">27</xref>]. Moreover, pharmacological applications of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidines have been extensively illustrated in various reports in the literature [<xref rid="B28-molecules-27-00321" ref-type="bibr">28</xref>,<xref rid="B29-molecules-27-00321" ref-type="bibr">29</xref>,<xref rid="B30-molecules-27-00321" ref-type="bibr">30</xref>,<xref rid="B31-molecules-27-00321" ref-type="bibr">31</xref>,<xref rid="B32-molecules-27-00321" ref-type="bibr">32</xref>,<xref rid="B33-molecules-27-00321" ref-type="bibr">33</xref>,<xref rid="B34-molecules-27-00321" ref-type="bibr">34</xref>,<xref rid="B35-molecules-27-00321" ref-type="bibr">35</xref>,<xref rid="B36-molecules-27-00321" ref-type="bibr">36</xref>,<xref rid="B37-molecules-27-00321" ref-type="bibr">37</xref>,<xref rid="B38-molecules-27-00321" ref-type="bibr">38</xref>]. In addition, the lead tricyclic compounds and the proposed target compounds incorporate a p-methoxyphenyl substitution akin to colchicine and CA-4 (<xref rid="molecules-27-00321-f001" ref-type="fig">Figure 1</xref>). The nature of the heteroatom substitution (S for NH) affects hydrogen bond (HB) strength [<xref rid="B39-molecules-27-00321" ref-type="bibr">39</xref>]. Thus, it was also of interest to isosterically replace the oxygen atom of the 4&#8242;-OCH<sub>3</sub> of <bold>4</bold>, <bold>8</bold> and <bold>9</bold> with a sulfur moiety to afford <bold>5</bold>, <bold>10</bold>, and <bold>11</bold>, in analogy to <bold>2</bold>.</p></list-item><list-item><label>(2)</label><p>Decrease numbers of sp2 bonds: Drug candidates show a higher clinical success rate with one or more sp3 hybridized carbon atoms as compared to &#8220;flat&#8221; molecules, due to low aqueous solubility of purely aromatic compounds [<xref rid="B40-molecules-27-00321" ref-type="bibr">40</xref>]. One of the major limitation of some MTAs, particularly the taxanes, is their poor water solubility [<xref rid="B41-molecules-27-00321" ref-type="bibr">41</xref>]. Thus, water-soluble MTAs are highly coveted, and an enormous effort continues to chemically modify and/or formulate analogues to increase their water solubility. Increasing &#8216;aromatic proportion&#8217; in a molecule has a detrimental effect on the solubility [<xref rid="B40-molecules-27-00321" ref-type="bibr">40</xref>]. The fraction of sp3 hybridized carbon atoms (Fsp3), in other words, the fraction of carbon atoms that are saturated, correlates positively with water solubility [<xref rid="B40-molecules-27-00321" ref-type="bibr">40</xref>]. In an attempt to both increase the water solubility as well to probe the potential interactions with the hydrophobic pocket in the CS, we designed target compounds <bold>4</bold>&#8211;<bold>14</bold> by incorporating sp3 hybridized carbon atoms in the tricyclic scaffold of the lead compounds <bold>1</bold>&#8211;<bold>3</bold>.</p></list-item><list-item><label>(3)</label><p>Variation of the substituents at the 2-position: Compound <bold>7</bold> was specifically designed to determine the effect of replacing the 2-NH<sub>2</sub> in <bold>4</bold> with a 2-H. This allows an exploration of the 2-NH<sub>2</sub> and hydrogen bond interactions with corresponding amino acids at the CS. It was also of our interest to observe the effect of isosteric replacement of 2-NH<sub>2</sub> on compound <bold>4</bold> with a 2-CH<sub>3</sub> to afford <bold>8</bold>. This would also provide information regarding the activity on the replacement of H with CH<sub>3</sub> at the 2-position in the tricyclic scaffold.</p></list-item><list-item><label>(4)</label><p>Conformational restriction: Conformational restriction or rigidification of a ligand can decrease the entropic penalty [<xref rid="B42-molecules-27-00321" ref-type="bibr">42</xref>]. The ligand can adopt a preferred conformation for binding, which might lead to enhanced potency for a given physiological target [<xref rid="B42-molecules-27-00321" ref-type="bibr">42</xref>]. In an effort to better define the conformational requirements for biological activities, we systematically incorporated various groups to restrict bond rotations. The conformation of <bold>9</bold> (<xref rid="molecules-27-00321-f003" ref-type="fig">Figure 3</xref>) is determined by three rotatable single bonds: the 4-position C-N bond (bond a), the 1&#8242;-position C-N bond (bond b) and the 4&#8242;-position C-O bond (bond c). Conformational analysis via molecular modeling and <sup>1</sup>H NMR studies [<xref rid="B25-molecules-27-00321" ref-type="bibr">25</xref>] suggest that the methyl group on the aniline nitrogen in <bold>1</bold> restricted the free rotation of bond a as well as bond b (<xref rid="molecules-27-00321-f002" ref-type="fig">Figure 2</xref>) and consequently restricted the conformation of the anilino ring. To study the significance of conformational restriction on biological activities, we first designed compounds <bold>8</bold> and <bold>9</bold>. In <bold>9,</bold> the rotation of bonds a and b was restricted by incorporating a methyl group at the N4- position to afford compound <bold>8</bold>. Incorporation of tetrahydroquinoline rings in <bold>6</bold> and <bold>12</bold> further restricted bond b of <bold>4</bold> and <bold>8</bold>. The design of compound <bold>13</bold> via the incorporation of a 5-methoxy naphthalene ring provided a further element of conformational restriction.</p></list-item></list></p></sec><sec id="sec2dot2-molecules-27-00321"><title>2.2. Molecular Modeling</title><p>Computational modeling studies were performed to elucidate the binding mode of the lead and target compounds <bold>1</bold>&#8211;<bold>14</bold> and probe the possible interactions with the CS. Compounds <bold>1</bold>&#8211;<bold>14</bold> were docked into the CS (PDB: 6BS2, 2.65 &#197;) [<xref rid="B43-molecules-27-00321" ref-type="bibr">43</xref>] of tubulin using Maestro, Schr&#246;dinger 2020-2, New York, NY, USA [<xref rid="B44-molecules-27-00321" ref-type="bibr">44</xref>]. <xref rid="molecules-27-00321-f004" ref-type="fig">Figure 4</xref>a shows the docked pose of <bold>4</bold> (cyan) superimposed with colchicine (pink) in the X-ray crystal structure of the CS [<xref rid="B43-molecules-27-00321" ref-type="bibr">43</xref>]. Multiple low-energy conformations (within &#8722;9.68 to &#8722;10.89 kcal/mol) were obtained on docking. The pyrimidine and cyclohexene rings of the tricyclic 4,5,6,7-tetrahydrobenzo thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine scaffold of <bold>4</bold>&#8211;<bold>14</bold> (compound <bold>4</bold>, <xref rid="molecules-27-00321-f004" ref-type="fig">Figure 4</xref>b is a representative of <bold>5</bold>&#8211;<bold>14</bold>) overlapped with the A- and C- rings of the colchicine, respectively. The concave structure created by the 4,5,6,7-tetrahydrobenzo thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine scaffold of <bold>4</bold>&#8211;<bold>14</bold> overlapped well with the B- ring of colchicine. The N1 of the pyrimidine and the 2-NH<sub>2</sub> of compounds <bold>4</bold>&#8211;<bold>6</bold> formed water-mediated hydrogen bond interactions with the backbone of Cys&#946;239. In compounds <bold>8</bold>&#8211;<bold>14,</bold> the 2-CH<sub>3</sub> interacted with the hydrophobic amino acids Val&#946;236 and Ile&#946;316. The cyclohexene ring of <bold>4</bold>&#8211;<bold>14</bold> formed hydrophobic interactions with Leu&#946;246, Ala&#946;248 and Met&#946;257. The N4-Me moiety of <bold>4</bold>, <bold>5</bold>, <bold>7</bold>, <bold>8</bold>, <bold>10</bold> and <bold>13</bold> formed hydrophobic interactions with Ala&#946;314 and Ala&#946;352. The 4&#8242;-OMe-Ph of <bold>4</bold>, <bold>6</bold>&#8211;<bold>9</bold> and <bold>12</bold>&#8211;<bold>14</bold> is oriented towards the pocket formed by polar amino acid residues Lys&#946;350, Thr&#946;312 and Asn&#946;256. The docked score of compound <bold>4</bold> was &#8722;10.89 kcal/mol, and for compounds <bold>5</bold>&#8211;<bold>14</bold>, the docked scores were in a range of &#8722;9.68 to &#8722;10.72 kcal/mol (<xref rid="app1-molecules-27-00321" ref-type="app">Supplementary Materials</xref>&#160;<xref rid="app1-molecules-27-00321" ref-type="app">Table S1</xref>). The pyrimidine ring of <bold>4</bold> overlaps with the pyrimidine ring of the crystalized ligand of 6BS2 (<xref rid="app1-molecules-27-00321" ref-type="app">Supplementary Materials</xref>&#160;<xref rid="app1-molecules-27-00321" ref-type="app">Figure S1</xref>).</p></sec><sec id="sec2dot3-molecules-27-00321"><title>2.3. Chemistry</title><p>Compounds <bold>4</bold>&#8211;<bold>14</bold> were synthesized according to the synthetic routes outlined in <xref rid="molecules-27-00321-sch001" ref-type="fig">Scheme 1</xref>, <xref rid="molecules-27-00321-sch002" ref-type="fig">Scheme 2</xref>, <xref rid="molecules-27-00321-sch003" ref-type="fig">Scheme 3</xref> and <xref rid="molecules-27-00321-sch004" ref-type="fig">Scheme 4</xref>. The Gewald reaction (<xref rid="molecules-27-00321-sch001" ref-type="fig">Scheme 1</xref>) was carried out on a solution of sulfur in ethanol, to which cyclohexanone <bold>15</bold> and ethyl cyanoacetate were added. Morpholine was added dropwise to the solution to obtain <bold>16</bold>. Cyclization of <bold>16</bold> with chloro-formamidine hydrochloride, formamide and acetonitrile afforded <bold>17</bold>, <bold>18</bold> and <bold>19</bold>, respectively, using reported methods [<xref rid="B25-molecules-27-00321" ref-type="bibr">25</xref>,<xref rid="B45-molecules-27-00321" ref-type="bibr">45</xref>,<xref rid="B46-molecules-27-00321" ref-type="bibr">46</xref>]. Chlorination [<xref rid="B47-molecules-27-00321" ref-type="bibr">47</xref>] of <bold>17</bold>&#8211;<bold>19</bold> with POCl<sub>3</sub> and pyridine in toluene afforded <bold>20</bold>&#8211;<bold>22</bold> in 68&#8211;75% yield.</p><p>The monomethylated aniline, 5-methoxy-<italic toggle="yes">N</italic>-methylnaphthalen-2-amine (<bold>26</bold>), was synthesized over three steps from 6-aminonaphthalen-1-ol (<bold>23</bold>) (<xref rid="molecules-27-00321-sch002" ref-type="fig">Scheme 2</xref>) [<xref rid="B48-molecules-27-00321" ref-type="bibr">48</xref>]. Boc protection of <bold>23</bold> in THF at r.t. yielded tert-butyl(5-hydroxyaphthalen-2-yl)carbamate (<bold>24</bold>) in 84% yield, followed by methylation with methyl iodide and sodium hydride to provide <bold>25</bold>. Finally, Boc deprotection [<xref rid="B49-molecules-27-00321" ref-type="bibr">49</xref>] using trifluoracetic acid (TFA) afforded 5-methoxy-<italic toggle="yes">N</italic>-methylnaphthalen-2-amine (<bold>26</bold>) in 91% yield.</p><p>Intermediates <bold>20</bold>&#8211;<bold>22</bold> were subjected to S<sub>N</sub>Ar reactions using appropriate anilines in isopropanol or toluene to afford final compounds <bold>4</bold>&#8211;<bold>7</bold>, <bold>9</bold>, <bold>11</bold>, <bold>12</bold> and <bold>14</bold> (<xref rid="molecules-27-00321-sch003" ref-type="fig">Scheme 3</xref>). Compounds <bold>9</bold>, <bold>11</bold> and <bold>14</bold> were dissolved in DMF, followed by portion-wise addition of sodium hydride and iodomethane. Reaction mixtures were stirred for 2 h at r.t. to afford final compounds <bold>8</bold>, <bold>10</bold> and <bold>13</bold>, respectively (<xref rid="molecules-27-00321-sch004" ref-type="fig">Scheme 4</xref>).</p></sec><sec id="sec2dot4-molecules-27-00321"><title>2.4. Biological Evaluations and Discussion</title><sec id="sec2dot4dot1-molecules-27-00321"><title>2.4.1. Antiproliferative and Microtubule Depolymerization Effects</title><p>We investigated the microtubule depolymerization and the antiproliferative activities of compounds <bold>4</bold>&#8211;<bold>14</bold> (<xref rid="molecules-27-00321-t002" ref-type="table">Table 2</xref>). At a concentration of 10 &#181;M, the compounds that caused at least 50% microtubule depolymerization were further evaluated to determine their EC<sub>50</sub> values, the concentration that causes the loss of 50% of cellular microtubules as visualized microscopically. Compounds that caused microtubule depolymerization at 10 &#956;M were further evaluated for antiproliferative potency in the drug-sensitive MDA-MB-435 cancer cell line, and the IC<sub>50</sub> (concentration required to cause 50% inhibition of proliferation) values were determined using the sulforhodamine B assay (SRB assay). Compound <bold>4</bold>, the 2-NH<sub>2</sub> analogue of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine, was the most potent compound of this series for both microtubule depolymerizing and antiproliferative effects, with an EC<sub>50</sub> of 19 nM and an IC<sub>50</sub> of 9.0 nM (<xref rid="molecules-27-00321-t002" ref-type="table">Table 2</xref>). Compound <bold>4</bold> was 7-fold more potent than <bold>1</bold> for microtubule depolymerizing effects, indicating that the 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine ring is significantly better for microtubule depolymerizing activity than the pyrimido[4,5-b]indole ring of <bold>1</bold> (<xref rid="molecules-27-00321-t002" ref-type="table">Table 2</xref>) and that it additionally contributes to improvements in antiproliferative potency. We next evaluated the importance of the 4&#8242;-OMe group of compound <bold>4</bold> by replacing it with an isosteric 4&#8242;-SMe (<bold>5</bold>). The resulting compound <bold>5</bold> was 15-fold more potent than the corresponding lead compound <bold>2</bold> with respect to microtubule depolymerization activity and was additionally 2.3-fold more potent for antiproliferative effects compared to <bold>2</bold>. Clearly, this further substantiated the importance of an S in the scaffold over an NH. However, comparing compounds <bold>4</bold> and <bold>5</bold> indicated that the 4&#8242;-OMe was better than the 4&#8242;-SMe. Compound <bold>6</bold>, the tetrahydroquinoline-substituted compound, a conformationally restricted analogue of <bold>4</bold> around bond b, was 6-fold less potent for antiproliferative effects and for microtubule depolymerizing effects than <bold>4</bold>, indicating that conformational restriction in <bold>6</bold> is detrimental to these biological activities.</p><p>We next focused on substituting the 2-position of the 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine. The corresponding 2-H analogue <bold>7</bold> of lead compound <bold>3</bold> displayed ~27-fold increased potency in the microtubule depolymerizing assay as compared with <bold>3</bold> (<xref rid="molecules-27-00321-t002" ref-type="table">Table 2</xref>), indicating a more effective engagement with tubulin. Compound <bold>7</bold> was 3.5-fold more potent than compound <bold>3</bold> for antiproliferative effects. The 2-Me analogue <bold>8</bold> displayed slightly less potency compared to the 2-H compound <bold>7</bold> for both microtubule depolymerizing and antiproliferative effects, yet it had 2.7- and 5.8-fold lower potency than the 2-NH<sub>2</sub> compound <bold>4</bold> in the microtubule depolymerization assay and antiproliferative assay, respectively. Compound <bold>8</bold> however, with a 2-Me, had a lower EC<sub>50</sub>/IC<sub>50</sub> ratio (1.0 for <bold>8</bold> as compared to 2.2 for <bold>4</bold>), indicating a tighter correlation between the microtubule depolymerizing effects and the cancer cell cytotoxicity. Compound <bold>10</bold> with a 4&#8242;-SMe group and a 2-Me analogue of compound <bold>5</bold> had 2-fold lower potency than <bold>5</bold> in both assays.</p><p>In compounds <bold>12</bold> and <bold>13</bold>, conformational restrictions of the N4-phenyl moiety of <bold>8</bold> about bond b with a 1,2,3,4-tetrahydroquinoline moiety and 5&#8242;-methoxy naphthalene, respectively, caused a 2.3&#8211;3-fold decrease in potency for <bold>12</bold> in antiproliferative and microtubule depolymerizing effects compared to <bold>8</bold> and a 1.5- to 2-fold drop in potency for <bold>13</bold> as compared to <bold>8</bold>. Compounds <bold>9</bold>, <bold>11</bold>, and <bold>14</bold> did not show any activity in the microtubule depolymerization assay, and these were not evaluated for antiproliferative effects, corroborating our previous reports that the N4-Me is crucial for MT activity [<xref rid="B26-molecules-27-00321" ref-type="bibr">26</xref>].</p><p>For compounds <bold>4</bold>&#8211;<bold>8</bold>, <bold>10</bold>, <bold>12</bold> and <bold>13,</bold> the EC<sub>50</sub>/IC<sub>50</sub> ratios (<xref rid="molecules-27-00321-t002" ref-type="table">Table 2</xref>) ranged from 1 to 2.2, which is better than the EC<sub>50</sub>/IC<sub>50</sub> ratios for lead compounds <bold>1</bold>&#8211;<bold>3</bold> (8.8, 12 and 9.2 for lead compounds <bold>1</bold>, <bold>2</bold> and <bold>3</bold>, respectively). These lower values for compounds <bold>4</bold>&#8211;<bold>8</bold>, <bold>10</bold>, <bold>12</bold> and <bold>13</bold> suggest a cytotoxic mechanism of action that is primarily microtubule-dependent.</p></sec><sec id="sec2dot4dot2-molecules-27-00321"><title>2.4.2. Inhibition of Tubulin Assembly and Colchicine Binding</title><p>Compounds <bold>4</bold>, <bold>5</bold>, <bold>7</bold>, <bold>8</bold> and <bold>10</bold> were evaluated for their direct effects on purified tubulin assembly and for inhibition of colchicine binding (<xref rid="molecules-27-00321-t003" ref-type="table">Table 3</xref>). Compounds <bold>4</bold>, <bold>5</bold>, <bold>7</bold>, <bold>8</bold> and <bold>10</bold> inhibited tubulin assembly with activities better than those of the lead compounds <bold>1</bold>&#8211;<bold>3</bold> as well as CA-4. Compound <bold>4</bold> was 2-fold more potent than the lead <bold>1</bold> as an inhibitor of tubulin assembly. On the other hand, compounds <bold>5</bold>, <bold>7</bold>, <bold>8</bold> and <bold>10</bold> were 2-fold more potent than the standard CA-4. Moreover, compounds <bold>5</bold> and <bold>7</bold> were 5-fold more potent as inhibitors of tubulin assembly than the corresponding lead compounds <bold>2</bold> and <bold>3</bold>, respectively. Compounds <bold>4</bold>, <bold>5</bold>, <bold>7</bold>, <bold>8</bold> and <bold>10</bold> inhibited the binding of [<sup>3</sup>H]colchicine to tubulin by 89&#8211;99%, whereas the lead compounds <bold>1</bold>, <bold>2</bold> and <bold>3</bold> showed 84, 67, and 62% inhibition of [<sup>3</sup>H]colchicine binding, respectively. Thus <bold>4</bold>, <bold>5</bold>, <bold>7</bold>, <bold>8</bold> and <bold>10</bold> were more active than the initial lead compounds <bold>1</bold>&#8211;<bold>3</bold>. These results clearly demonstrated that these compounds are CS MTAs.</p></sec><sec id="sec2dot4dot3-molecules-27-00321"><title>2.4.3. Effect on &#946;III-Tubulin and Pgp-Mediated Cancer Cell Resistance</title><p>Compounds <bold>4</bold>&#8211;<bold>8</bold>, <bold>10</bold>, <bold>12</bold>, and <bold>13</bold> were evaluated for their abilities to overcome &#946;III-tubulin mediated drug resistance using an isogenic HeLa cell line pair (<xref rid="molecules-27-00321-t004" ref-type="table">Table 4</xref>). Consistent with the results obtained in MDA-MB-535 cells, compound <bold>4</bold> was the most potent in the series in the HeLa and HeLa WT &#946;III cell lines, with 1.6-fold higher potency than the lead compound <bold>1</bold>. Compounds <bold>5</bold> and <bold>7</bold> showed 2-fold higher potency than the lead compounds <bold>2</bold> and <bold>3</bold> in HeLa and HeLa WT &#946;III cell lines. The Rr values (<xref rid="molecules-27-00321-t004" ref-type="table">Table 4</xref>) were calculated by dividing the IC<sub>50</sub> of the &#946;III-tubulin expressing line by the IC<sub>50</sub> obtained in the parental HeLa cells. The expression of &#946;III-tubulin is known to lead to paclitaxel resistance, and paclitaxel has an Rr value of 8.6 in this cell line pair (<xref rid="molecules-27-00321-t004" ref-type="table">Table 4</xref>). The target compounds <bold>3</bold>&#8211;<bold>8</bold>, <bold>10</bold>, <bold>12</bold>, and <bold>13</bold> have Rr values ~1.0 (<xref rid="molecules-27-00321-t004" ref-type="table">Table 4</xref>), suggesting that they circumvent &#946;III-tubulin mediated drug resistance, in contrast to paclitaxel.</p><p>The potent MTAs <bold>4</bold>&#8211;<bold>8</bold>, <bold>10</bold>, <bold>12</bold>, and <bold>13</bold> were also evaluated for their activity in the SK-OV-3 ovarian carcinoma cell line and the Pgp-expressing subline SK-OV-3 MDR1-M6/6 (<xref rid="molecules-27-00321-t004" ref-type="table">Table 4</xref>). In these cell lines, compound <bold>4</bold> was again the most potent compound in the series. Comparison of the IC<sub>50</sub> values in the parental SK-OV-3 and genetically manipulated SK-OV-3 MDR1-M6/6 cell line allows for the calculation of a relative resistance value, designated Rr. This value is calculated by dividing the IC<sub>50</sub> value obtained in the Pgp-expressing SK-OV-3 MDR1-M6/6 cells by the IC<sub>50</sub> obtained in the parental SK-OV-3 cells. Paclitaxel, a known Pgp substrate, has an Rr value of 240, while CA-4, a poor Pgp substrate, has an Rr value of 1.3 (<xref rid="molecules-27-00321-t004" ref-type="table">Table 4</xref>). Compound <bold>4</bold> had IC<sub>50</sub> values in SK-OV-3 and SK-OV-3 MDR1-M6/6 cells comparable to that of CA-4 and an Rr of 1.5, indicating that it is able to overcome drug resistance mediated by Pgp. Here, a correlation between a cell-based assay and a biochemical assay is not always observed, which might be due in part to the ability of the compounds to cross the cell membrane and accumulate intracellularly. Compounds <bold>5</bold>&#8211;<bold>8</bold>, <bold>10</bold>, <bold>12</bold>, and <bold>13</bold> also had Rr values &#8804; 1.5, suggesting that they are all poor substrates for Pgp-mediated transport and have advantages over the taxanes and vinca alkaloids in multidrug-resistant cancer cells.</p></sec><sec id="sec2dot4dot4-molecules-27-00321"><title>2.4.4. Activity of Compound <bold>4</bold> in the NCI Cancer Cell Line Panel</title><p>Compound <bold>4</bold>, the most potent compound of the series, was selected for evaluation in the NCI-60 cancer cell line panel [<xref rid="B50-molecules-27-00321" ref-type="bibr">50</xref>], and it had a GI<sub>50</sub> (concentration causing 50% inhibition of cell proliferation) of ~10 nM against 40 of the 60 cancer cell lines (<xref rid="molecules-27-00321-t005" ref-type="table">Table 5</xref>). Compound <bold>4</bold> had better potency than the lead compound <bold>1</bold> in 50 cancer cell lines. (better by 5 to 6-fold in leukemia, 2 to 17-fold in NSCLC, 2 to 6-fold in colon cancer, 2 to 5-fold in CNS cancer, 2 to 25-fold in melanoma, 2 to 5-fold in ovarian cancer, 2 to 9-fold in renal cancer, 2 to 5-fold in prostate cancer, and 2 to 6-fold in breast cancer compared to lead compound <bold>1</bold>) [<xref rid="B26-molecules-27-00321" ref-type="bibr">26</xref>]. Thus <bold>4</bold>, the thiophene-fused analogue, is up to 25-fold more potent than our previously published lead [<xref rid="B26-molecules-27-00321" ref-type="bibr">26</xref>].</p></sec><sec id="sec2dot4dot5-molecules-27-00321"><title>2.4.5. Antitumor Activity of Compound <bold>4</bold> in MDA-MB-435 Xenografts</title><p>Compound <bold>4</bold> was selected for further evaluation in an in vivo xenograft mouse study in light of its nanomolar potency in vitro in the NCI-60 cancer cell line panel and its potent microtubule depolymerization activity. The in vivo effects of <bold>4</bold> were tested in the MDA-MB-435 xenograft model (<xref rid="molecules-27-00321-f005" ref-type="fig">Figure 5</xref>). After conducting initial dose tolerance testing, <bold>4</bold> was administered at a dose of 75 mg/kg 3 &#215; a week where it caused moderate weight loss yet had statistically significant antitumor effects as compared to the control at day 14, the end of the trial. In this trial, there was a trend toward antitumor effects with paclitaxel (15 mg/kg), but this did not reach statistical significance at any day or at trial conclusion.</p></sec></sec></sec><sec id="sec3-molecules-27-00321"><title>3. Materials and Methods</title><sec id="sec3dot1-molecules-27-00321"><title>3.1. Chemistry</title><p>All evaporations were carried out under a vacuum using a rotary evaporator. Analytical samples were dried in vacuo (0.2 mmHg) in a CHEM-DRY drying apparatus over P<sub>2</sub>O<sub>5</sub> at 50 &#176;C. Thin-layer chromatography (TLC) was performed on Whatman Sil G/UV254 silica gel plates (Whatman International Ltd., Maidstone, England), and the spots were visualized by irradiation at 254 nm. Proportions of solvents used for TLC are by volume. All analytical samples were homogeneous on TLC in at least two different solvent systems. Column chromatography was performed on a 70&#8211;230 mesh silica gel (Fisher Scientific, Waltham, MA, USA) column. The amount (weight) of silica gel for column chromatography was in the range of 50&#8211;100 times the amount (weight) of the crude compounds being separated. Columns were wet-packed with appropriate solvent unless specified otherwise. Melting points were determined using a digital MEL-TEMP II melting point apparatus with FLUKE 51 K/J electronic thermometer or using an MPA100 OptiMelt (Stanford Research Systems, Sunnyvale, CA, USA) automated melting point system and are uncorrected. Nuclear magnetic resonance spectra for protons (<sup>1</sup>H NMR) were recorded on Bruker Avance II 400 (Billerica, MA, USA) (400 MHz) and 500 (500 MHz) systems and were analyzed using MestReC NMR (Mestrelab research, San Diego, CA, USA, data processing software. The chemical shift (&#948;) values are expressed in ppm (parts per million) relative to tetramethylsilane as an internal standard: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad singlet; exch, protons exchangeable by addition of D<sub>2</sub>O.</p><p>Elemental analyses or high-performance liquid chromatography (HPLC)/mass analysis were used to determine the purities of the target compounds. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA, USA. Elemental compositions are within &#177;0.4% of the calculated values and indicate &gt;95% purity. Fractional moles of water or organic solvents found in some analytical samples could not be removed despite 24&#8211;48 h of drying in vacuo and were confirmed where possible by their presence in the <sup>1</sup>H NMR spectra. Mass spectral data were acquired on an Agilent G6220AA TOF LC/MS system using the nano ESI (Agilent chip tube system with infusion chip). HPLC analysis was performed on a Waters HPLC system using a XSelect CSH C18 column. Peak area of the major peak versus other peaks was used to determine purity. All solvents and chemicals were purchased from Sigma-Aldrich Co, USA. or Fisher Scientific Inc, USA. and were used as received.</p><p>Ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (<bold>16</bold>): 4-Cyclohexanone <bold>15</bold> (5.27 mL, 50.95 mmol) and morpholine (4.39 mL, 50.95 mmol) were added to a mixture of ethyl cyanoacetate (5.42 mL, 50.95 mmol) and sulfur (13.07 g, 50.95 mmol) in ethanol (25 mL). The mixture was stirred at room temperature for 1 h, then at 60 &#176;C for 12 h. The reaction mixture was cooled to room temperature, and the solvent was removed in vacuo. The crude product was purified by flash column chromatography on a silica column using hexane/ethyl acetate (10:1) as eluent to obtain compound <bold>16</bold> (7.80 g, 34.64 mmol, 68% yield) as a light-yellow solid. TLC Rf = 0.67 (hexane: EtOAc, 3:1); mp, 194&#8211;195.7 &#176;C (lit. [<xref rid="B51-molecules-27-00321" ref-type="bibr">51</xref>]192&#8211;193 &#176;C); <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#948; 6.66 (s, 2H, br, exch., NH<sub>2</sub>), 4.36 (q, J = 7.0 Hz, 2H, -<underline>CH<sub>2</sub></underline>CH<sub>3</sub>), 2.60 (m, 2H, -CH<sub>2</sub>), 2.41 (m, 2H, -CH<sub>2</sub>), 1.68&#8211;1.65 (m, 4H, -CH<sub>2</sub>), 1.42 (t, J = 7.0 Hz, 3H, -CH<sub>2</sub><underline>CH<sub>3</sub></underline>). The <sup>1</sup>H-NMR matches the <sup>1</sup>H-NMR of the reported compound in the literature [<xref rid="B51-molecules-27-00321" ref-type="bibr">51</xref>]. This compound was used for the next reaction without further characterization.</p><p>2-Amino-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidin-4(3H)-one (<bold>17</bold>): Methyl sulfone (15 g), intermediate <bold>16</bold> (5.0 g, 22.19 mmol) and chloroformamidine hydrochloride (5.10 g, 44.38 mmol) were mixed in a round bottom flask. The reaction mixture was stirred at 140 &#176;C for 4 h. The reaction was quenched with 100 mL water, cooled in an ice bath and basified to pH 8.0 using an aqueous NH<sub>4</sub>OH solution. The precipitate was collected by filtration, dried (using Na<sub>2</sub>SO<sub>4</sub>) and afforded 3.24 g (66%) of <bold>17</bold> as a brown solid. TLC Rf = 0.60 (CHCl<sub>3</sub>: MeOH, 5:1). The product <bold>17</bold> was not purified further and taken to the next step without characterization.</p><p>4-Chloro-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidin-2-amine (<bold>20</bold>): Compound <bold>17</bold> (1.96 g, 8.84 mmol) was chlorinated with phosphorus oxychloride (0.80 mL, 8.84 mmol) and pyridine (0.7 mL, 8.84 mmol) in toluene (15 mL). The reaction was kept at reflux for 4 h. The POCl<sub>3</sub> was evaporated, and the mixture was cooled in an ice bath. The mixture was neutralized using an aqueous NH<sub>4</sub>OH solution to yield a precipitate. The precipitate was collected by filtration, washed with water, dried and dissolved in MeOH. To the solution was added silica gel (1 g), and the solvent was removed under reduced pressure to provide a silica gel plug. Column chromatography was performed with hexane and ethyl acetate (10:1) to generate <bold>20</bold> (2.0 g, 6.19 mmol, 70%) as a brown solid. TLC Rf = 0.68 (hexane: EtOAc, 3:1); mp 234 &#176;C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>): &#948; 5.28 (s, br, 2H, exch., 2-NH<sub>2</sub>), 2.74 (t, 2H, -CH<sub>2</sub>), 1.92 (t, 2H, -CH<sub>2</sub>), 1.56&#8211;1.50 (m, 2H, -CH<sub>2</sub>), 1.43&#8211;1.38 (m, 2H, -CH<sub>2</sub>). This compound was used for the next reaction without further characterization.</p><p>4-Chloro-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine (<bold>21</bold>): Treatment of <bold>16</bold> (5.0 g, 22.19 mmol) with formamide (4.42 mL, 110.96 mmol) was carried out in a microwave vessel at 180 &#176;C for 12 h. The reaction was cooled to room temperature, and 50 mL water was added to the mixture. The precipitate was collected and dried under high vacuum to afford <bold>18</bold> as a white solid in 72% yield (3.30 g). The product <bold>18</bold> was taken to the next step without characterization. Chlorination of <bold>18</bold> (3.0 g, 14.54 mmol) was performed using POCl<sub>3</sub> (1.4 mL, 14.54 mmol) and pyridine (1.17 mL, 14.54 mmol), and the mixture was kept at reflux for 8 h. The solvent was removed by evaporation, and the residue was neutralized with ammonia in water solution to generate a pale-yellow precipitate. The precipitate was collected by filtration. To the precipitate was added methanol and 2.0 g of silica gel. The solvent was removed under reduced pressure, and a silica plug was prepared. A flash column chromatographic separation was performed using ethyl acetate-hexane as eluent to afford 1.96 g of <bold>21</bold> (8.73 mmol, 60%) as a pale-yellow solid. TLC Rf = 0.77 (Hexane: EtOAc, 3:1); mp, 210&#8211;112 &#176;C; <sup>1</sup>H NMR (400 Hz) (Me<sub>2</sub>SO-d<sub>6</sub>) &#948; 8.51 (s, 1H, Ar), 2.86&#8211;2.82 (m, 2H, -CH<sub>2</sub>), 2.78&#8211;2.74 (m, 2H, -CH<sub>2</sub>), 1.84&#8211;1.78 (m, 4H, -CH<sub>2</sub>CH<sub>2</sub>). Anal. Calcd. for C<sub>10</sub>H<sub>9</sub>ClN<sub>2</sub>S: C, 53.45; H, 4.04; Cl, 15.78, N, 12.47; S, 14.27. Found: C, 53.58; H, 4.07; Cl, 15.57, N, 12.37; S, 14.12.</p><p>2-Methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidin-4(3H)-one (<bold>19</bold>): Compound <bold>16</bold> (2.5 g, 11.10 mmol) was dissolved in 20 mL of acetonitrile and hydrogen chloride gas was bubbled through for 30 min. The mixture was stirred at room temperature overnight. The residue was dissolved in 10 mL distilled water and treated with ammonia in water solution to generate a white precipitate. The precipitate was collected by filtration to afford 1.27 g (5.77 mmol, 52%) of <bold>19</bold> as a white solid. TLC Rf = 0.11 (hexane: EtOAc, 3:1); mp &gt;250 &#176;C (lit. [<xref rid="B51-molecules-27-00321" ref-type="bibr">51</xref>] 285 &#176;C) <sup>1</sup>H NMR (400 MHz, DMSO-d6): &#948; 12.10 (s, 1H, exch., -NH), 3.02&#8211;2.95 (m, 2H, -CH<sub>2</sub>-), 2.87&#8211;2.84 (m, 2H, -CH<sub>2</sub>-), 2.66 (s, 3H, -CH<sub>3</sub>), 1.84 (t, J = 3.1 Hz, 4H, -CH<sub>2</sub>-). This compound was used for the next reaction without further characterization.</p><p>4-Chloro-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine (<bold>22</bold>): Chlorination of <bold>18</bold> (1.0 g, 4.54 mmol) was carried out using POCl<sub>3</sub> (0.63 mL, 6.81 mmol) and pyridine (0.54 mL, 6.81 mmol) in 15 mL of xylene under reflux for 6 h. The solvent was evaporated and neutralized with ammonia in water solution to generate a light-yellow precipitate. The precipitate was collected by filtration to afford <bold>22</bold> as a light-yellow solid (704.42 mg, 2.95 mmol, 65%). TLC Rf = 0.83 (hexane: EtOAc, 3:1); mp, 228&#8211;230 &#176;C; <sup>1</sup>H NMR (400 Hz) (Me<sub>2</sub>SO-d<sub>6</sub>) &#948; 2.79&#8211;2.85 (m, 2H, -CH<sub>2</sub>-), 2.84&#8211;2.80 (m, 2H, -CH<sub>2</sub>-), 2.58 (s, 3H, -CH<sub>3</sub>), 1.81&#8211;1.77 (m, 4H, -CH<sub>2</sub>-). This compound was used for the next reaction without further characterization.</p><sec><title>General Procedure for Synthesis of 4&#8211;14</title><p>Compounds <bold>20</bold>&#8211;<bold>22</bold> were dissolved in isopropanol, followed by addition of 1&#8211;2 drops of HCl and the appropriate anilines. The reaction mixture was stirred for 4&#8211;8 h at reflux. The reaction mixture was cooled, and silica gel was added to the solvent mixture to prepare a silica gel plug. A flash column chromatographic separation was performed using ethyl acetate-hexane as eluent to afford <bold>4</bold>&#8211;<bold>7</bold>, <bold>9</bold>, <bold>11</bold>, <bold>12</bold> and <bold>14</bold> with yields of 48&#8211;68%. Compounds <bold>9</bold>, <bold>11</bold> and <bold>14</bold> were added to NaH in DMF with drop-wise addition of iodomethane to obtain <bold>8</bold>, <bold>10</bold> and <bold>13</bold>, respectively, in 57&#8211;70% yield.</p><p>N4-(4-methoxyphenyl)-N4-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine-2,4-diamine (<bold>4</bold>): To a solution of <bold>20</bold> (250 mg, 1.04 mmol) in isopropanol (20 mL), 1&#8211;2 drops of HCl were added, followed by addition of 4-methoxy-<italic toggle="yes">N</italic>-methylaniline (157.3 mg, 1.15 mmol), followed by reflux for 6 h. The reaction mixture was cooled to room temperature, silica gel (500 mg) was added, and the solvent was removed under reduced pressure. Purification was performed by column chromatography using 1% MeOH in CHCl<sub>3</sub> as the eluant, and fractions containing the product (TLC) were pooled. The solvent was evaporated to give a white solid that was washed with CHCl<sub>3</sub> to afford 230.0 mg (65% yield) of <bold>4</bold>. TLC Rf = 0.40 (CHCl<sub>3</sub>: MeOH, 20:1); mp 167&#8211;168.1 &#176;C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#948; 6.93 (d, J = 9.0 Hz, 2H, Ar), 6.82 (d, J = 9.0 Hz, 2H, Ar), 5.19 (s, br, 2H, exch., 2-NH<sub>2</sub>), 3.81 (s, 3H, -OCH<sub>3</sub>), 3.46 (s, 3H, N<sub>4</sub>-CH<sub>3</sub>), 2.67&#8211;2.63 (m, 2H, -CH<sub>2</sub>), 1.66&#8211;1.60 (m, 4H, -CH<sub>2</sub>CH<sub>2</sub>), 1.49&#8211;1.45 (m, 2H, -CH<sub>2</sub>). Anal. Calcd. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>OS 0.29 H<sub>2</sub>O: C, 62.54; H, 6.00; N, 16.20; S, 9.27. Found: C, 62.58; H, 6.03; N, 16.10; S, 9.21.</p><p>N4-methyl-N4-(4-(methylthio)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>] pyrimidine-2,4-diamine (<bold>5</bold>): To a solution of <bold>20</bold> (150 mg, 0.625 mmol) in toluene (8 mL), 1&#8211;2 drops of HCl were added, followed by addition of <italic toggle="yes">N</italic>-methyl-4-(methylthio)aniline (105.5 mg, 0.688 mmol), and the mixture was kept under reflux for 6 h. The reaction mixture was cooled to room temperature, silica gel (500 mg) was added, and the solvent was removed under reduced pressure. Purification was performed by column chromatography using 1% MeOH in CHCl<sub>3</sub> as the eluant, and the fractions containing the product (TLC) were pooled. The solvent was evaporated to give a pale-yellow solid that was washed with CHCl<sub>3</sub> to afford 109.0 mg (49% yield) of <bold>5</bold>. TLC Rf = 0.35 (CHCl<sub>3</sub>: MeOH, 20:1); mp 172&#8211;173.5 &#176;C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#948; 7.12 (d, J = 9.0 Hz, 2H, Ar), 6.97 (d, J = 9.0 Hz, 2H, Ar), 5.53 (s, br, 2H, exch., 2-NH<sub>2</sub>), 3.51 (s, 3H, N<sub>4</sub>-CH<sub>3</sub>), 2.39 (s, 3H, -CH<sub>3</sub>), 2.68&#8211;2.64 (m, 2H, -CH<sub>2</sub>-), 1.67&#8211;1.59 (m, 4H, -CH<sub>2</sub>CH<sub>2</sub>-), 1.48&#8211;1.44 (m, 2H, -CH<sub>2</sub>). Anal. Calcd. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>S<sub>2</sub> 0.18 CH<sub>3</sub>OH: C, 60.26; H, 5.77; N, 15.46; S, 17.69. Found: C, 60.24; H, 5.82; N, 15.47; S, 17.72.</p><p>4-(6-Methoxy-3,4-dihydroquinolin-1(2H)-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]- pyrimidin-2-amine (<bold>6</bold>): To a solution of <bold>20</bold> (100 mg, 0.417 mmol) in isopropanol (8 mL), 1&#8211;2 drops of HCl were added, followed by addition of 6-methoxy-1,2,3,4-tetrahydroquinoline (75.0 mg, 0.458 mmol), and the mixture was kept under reflux. The reaction mixture was cooled to room temperature, silica gel (250 mg) was added, and the solvent was removed under reduced pressure. Purification was performed by column chromatography using 1% MeOH in CHCl<sub>3</sub> as the eluant, and the fractions containing the product (TLC) were pooled. The solvent was evaporated to give an off-white solid that was then washed with CHCl<sub>3</sub> to afford 81.48 mg (48% yield) of <bold>6</bold>. TLC Rf = 0.32 (CHCl<sub>3</sub>: MeOH, 20:1); mp 190&#8211;191.8 &#176;C; <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#948; 6.79 (d, J = 2.9 Hz, 1H, Ar), 6.56 (dd, J = 8.9, 3.0 Hz, 1H, Ar), 6.39 (d, J = 8.8 Hz, 1H, Ar), 5.18 (s, br, 2H, exch., 2-NH<sub>2</sub>), 3.95&#8211;3.88 (m, 2H, -CH<sub>2</sub>), 3.82 (s, 3H, -OCH<sub>3</sub>), 2.75 (t, J = 6.5 Hz, 2H, -CH<sub>2</sub>), 2.68&#8211;2.64 (m, 2H, -CH<sub>2</sub>), 1.94&#8211;188 (m, 2H, -CH<sub>2</sub>), 1.68&#8211;1.61 (m, 4H, -CH<sub>2</sub>CH<sub>2</sub>), 1.49&#8211;1.45 (m, 2H, -CH<sub>2</sub>). HRMS (ESI) calculated for C<sub>20</sub>H<sub>22</sub>N<sub>4</sub>OS [M+H]<sup>+</sup>, 367.48. Found: 366.80. HPLC analysis: retention time, 13.63 min; peak area, 95.51%; eluent A, H<sub>2</sub>O: eluent B, ACN; gradient elution (100% H<sub>2</sub>O to 10% H<sub>2</sub>O) over 60 min with flow rate of 0.5 mL/min and detection at 245 nm; column temperature, room temperature.</p><p><italic toggle="yes">N</italic>-(4-methoxyphenyl)-<italic toggle="yes">N</italic>-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidin-4-amine (<bold>7</bold>): To a solution of <bold>22</bold> (200 mg, 0.890 mmol) in isopropanol (10 mL), 1&#8211;2 drops of HCl were added, followed by addition of 4-methoxy-<italic toggle="yes">N</italic>-methylaniline (134.0 mg, 0.979 mmol), and the mixture was kept under reflux for 6 h. The reaction mixture was cooled to room temperature, silica gel (400 mg) was added, and the solvent was removed under reduced pressure. Purification was performed by column chromatography using hexane and ethyl acetate (10:1) to give 98.50 mg (68% yield) of <bold>7</bold> as a white solid. TLC Rf = 0.48 (hexane: EtOAc, 3:1); mp 186.0&#8211;188.0 &#176;C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#948; 8.58 (s, 1H, Ar), 6.93 (d, J = 9.1 Hz, 2H, Ar), 6.86 (d, J = 9.1 Hz, 2H, Ar), 3.71 (s, 3H, -OCH<sub>3</sub>), 3.42 (s, 3H, N<sub>4</sub>-CH<sub>3</sub>), 2.72 (t, 2H, -CH<sub>2</sub>), 1.74 (t, J = 6.1 Hz, 2H, -CH<sub>2</sub>), 1.61&#8211;1.50 (m, 2H, -CH<sub>2</sub>), 1.46&#8211;1.35 (m, 2H, -CH<sub>2</sub>). Anal. Calcd. for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>OS: C, 66.43; H, 5.88; N, 12.91; S, 9.85. Found: C, 66.72; H, 5.79; N, 12.88; S, 9.66.</p><p><italic toggle="yes">N</italic>-(4-methoxyphenyl)-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidin-4-amine (<bold>9</bold>): Compound <bold>22</bold> (250 mg, 1.05 mmol) was dissolved in isopropanol (10 mL), followed by the addition of 1&#8211;2 drops of HCl and reacted with p-anisidine (0.15 mL, 1.36 mmol) for 4 h at reflux. The reaction mixture was cooled, and silica gel was added to the solvent mixture to prepare a silica gel plug. A flash column chromatographic separation was performed using ethyl acetate-hexane as eluent to afford intermediate <bold>9</bold> as a white solid (170.0 mg, 50% yield); TLC Rf = 0.22 (hexane: EtOAc, 3:1). mp, 208.4&#8211;210.1 &#176;C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#948; 8.04 (s, 1H, br, exch., NH), 7.71 (d, J = 8.8 Hz, 2H), 7.31 (d, J = 8.8 Hz, 2H), 3.82 (s, 3H, -OCH<sub>3</sub>), 3.16&#8211;3.08 (m, 2H, -CH<sub>2</sub>), 2.85&#8211;2.76 (m, 2H, -CH<sub>2</sub>), 2.48 (s, 3H, -CH<sub>3</sub>), 1.88&#8211;1.78 (m, 4H, -CH<sub>2</sub>). HRMS (ESI) calculated for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>OS [M+H]<sup>+</sup>, 326.12. Found: 326.08. HPLC analysis: retention time, 10.10 min; peak area, 95.10%; eluent A, H<sub>2</sub>O: eluent B, ACN; gradient elution (100% H<sub>2</sub>O to 10% H<sub>2</sub>O) over 60 min with flow rate of 0.5 mL/min and detection at 240 nm; column temperature, room temperature.</p><p><italic toggle="yes">N</italic>-(4-methoxyphenyl)-<italic toggle="yes">N</italic>,2-dimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidin-4-amine (<bold>8</bold>): Compound <bold>9</bold> (150 mg, 0.460 mmol) was dissolved in DMF (10 mL), followed by portion-wise addition of sodium hydride (60% in mineral oil) (18.44 mg, 0.460 mmol). Iodomethane (0.29 mL, 0.460 mmol) dissolved in 5 mL of DMF was added drop-wise to the suspension. The reaction was stirred for 2 h at room temperature. Silica gel was added to the solvent mixture and a plug was prepared. A flash column chromatographic separation was performed using ethyl acetate hexane as eluent to afford <bold>8</bold> as a white solid (106.0 mg, 68% yield); TLC Rf = 0.41 (hexane: EtOAc, 3:1); mp, 198&#8211;199.6 &#176;C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#948; 6.92 (d, J = 9.1 Hz, 2H, Ar), 6.86 (d, J = 9.1 Hz, 2H, Ar), 3.72 (s, 3H, -OCH<sub>3</sub>), 3.42 (s, 3H, N<sub>4</sub>-CH<sub>3</sub>), 2.70 (t, J = 6.4 Hz, 2H,-CH<sub>2</sub>), 2.56 (s, 3H, 2-CH<sub>3</sub>), 1.72 (t, J = 6.0 Hz, 2H, -CH<sub>2</sub>), 1.60&#8211;1.52 (m, 2H, -CH<sub>2</sub>), 1.46&#8211;1.34 (m, 2H, -CH<sub>2</sub>). Anal. Calcd. for C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>OS: C, 67.22; H, 6.24; N, 12.37; S, 9.45. Found: C, 67.38; H, 6.23; N, 12.31; S, 9.44.</p><p>2-Methyl-<italic toggle="yes">N</italic>-(4-(methylthio)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidin-4-amine (<bold>11</bold>): Compound <bold>22</bold> (300 mg, 1.26 mmol) was dissolved in toluene (10 mL), followed by addition of 1&#8211;2 drops of HCl and reacted with 4-(methylthio)aniline (227.43 mg, 1.63 mmol) for 6 h at reflux. The reaction mixture was cooled, and silica gel was added to the solvent mixture with the preparation of a plug. A flash column chromatographic separation was performed using ethyl acetate-hexane as eluent to afford intermediate <bold>11</bold> as a pale yellow solid (266.0 mg, 62% yield); TLC Rf = 0.15 (hexane: EtOAc, 3:1). mp, 201&#8211;202 &#176;C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#948; 8.02 (s, 1H, br, exch., NH), 7.67 (d, J = 8.7 Hz, 2H, Ar), 7.27 (d, J = 8.7 Hz, 2H, Ar), 3.14&#8211;3.05 (m, 2H, -CH<sub>2</sub>), 2.83&#8211;2.77 (m, 2H, -CH<sub>2</sub>), 2.48 (s, 3H, -CH<sub>3</sub>), 2.45 (s, 3H, -CH<sub>3</sub>), 1.89&#8211;1.79 (m, 4H, -CH<sub>2</sub>). Anal. Calcd. for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>S<sub>2</sub> 0.17 C<sub>6</sub>H<sub>5</sub>CH<sub>3</sub> 0.12 HCl: C, 63.76; H, 5.71; N, 11.63; S, 17.75. Found: C, 63.77; H, 5.56; N, 11.76; S, 17.65.</p><p><italic toggle="yes">N</italic>,2-dimethyl-<italic toggle="yes">N</italic>-(4-(methylthio)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidin-4-amine (<bold>10</bold>): Compound <bold>11</bold> (200 mg, 0.585 mmol) without further characterization was dissolved in DMF (10 mL), followed by portion-wise addition of sodium hydride (60% in mineral oil) (23.42 mg, 0.585 mmol). To the suspension was added drop-wise iodomethane (0.37 mL, 0.585 mmol) dissolved in 5 mL of DMF. The reaction was stirred for 2 h at room temperature. Silica gel was added to the solvent mixture, and a plug was prepared. A flash column chromatographic separation was performed using ethyl acetate hexane as eluent to afford <bold>10</bold> as a yellow solid (145.0 mg, 70% yield); TLC Rf = 0.45 (hexane: EtOAc, 3:1); mp, 189&#8211;191 &#176;C; <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#948; 7.16 (d, J = 8.8 Hz, 2H, Ar), 6.85 (d, J = 8.8 Hz, 2H, Ar), 3.41 (s, 3H, N<sub>4</sub>-CH<sub>3</sub>), 2.69 (t, J = 6.2 Hz, 2H, -CH<sub>2</sub>), 2.55 (s, 3H, 2-CH<sub>3</sub>), 2.41 (s, 3H, -SCH<sub>3</sub>), 1.83 (t, J = 6.0 Hz, 2H, -CH<sub>2</sub>), 1.62&#8211;1.50 (m, 2H, -CH<sub>2</sub>), 1.46&#8211;1.37 (m, 2H, -CH<sub>2</sub>). Anal. Calcd. for C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>S<sub>2</sub>: C, 64.19; H, 5.95; N, 11.82; S, 18.04. Found: C, 64.44; H, 5.99; N, 11.70; S, 17.78.</p><p>4-(6-Methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine (<bold>12</bold>): Compound <bold>22</bold> (250 mg, 1.05 mmol) was dissolved in isopropanol, followed by addition of 1&#8211;2 drops of HCl and 6-methoxy-1,2,3,4-tetrahydroquinoline (188 mg, 1.15 mmol). The reaction mixture was stirred for 8 h at reflux. The reaction mixture was cooled, and silica gel was added to the solvent mixture with the preparation of a plug. A flash column chromatographic separation was performed using hexane and ethyl acetate as eluent to afford <bold>12</bold> as a yellow solid (210 mg, 55% yield); TLC Rf = 0.53 (hexane: EtOAc, 3:1); mp, 199.0&#8211;201.0 &#176;C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#948; 6.78 (d, J = 3.1 Hz, 1H, Ar), 6.54 (dd, J = 8.8 Hz, J = 3.1 Hz, 1H, Ar), 6.34 (d, J = 8.8 Hz, 1H, Ar), 3.80&#8211;3.71 (m, 2H, -CH<sub>2</sub>), 3.69 (s, 3H, -OCH<sub>3</sub>), 3.48&#8211;3.42 (m, 2H, -CH<sub>2</sub>), 2.82&#8211;2.70 (m, 4H, -CH<sub>2</sub>), 2.54 (s, 3H, 2-CH<sub>3</sub>), 1.99&#8211;1.92 (m, 2H, -CH<sub>2</sub>), 1.68&#8211;1.58 (m, 2H, -CH<sub>2</sub>), 1.51&#8211;1.40 (m, 2H, -CH<sub>2</sub>). Anal. Calcd. for C<sub>21</sub>H<sub>23</sub>N<sub>3</sub>OS 0.39 (CH<sub>3</sub>)<sub>2</sub>CHOH: C, 68.46; H, 6.77; N, 10.79; S, 8.24. Found: C, 68.78; H, 6.39; N, 10.52; S, 7.91.</p><p>6-((2-Methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno [2,3-<italic toggle="yes">d</italic>]pyrimidin-4-yl)amino)naphthalen-1-ol (<bold>14</bold>): Compound <bold>22</bold> (300 mg, 1.26 mmol) was dissolved in isopropanol, followed by addition of 1&#8211;2 drops of HCl and reacted with 6-aminonaphthalen-1-ol (220 mg, 1.38 mmol) for 6 h at reflux. The reaction mixture was cooled, and silica gel was added to the solvent mixture to prepare a plug. A flash column chromatographic separation was performed using ethyl acetate-hexane as eluent to afford intermediate <bold>14</bold> as a pale-yellow solid (295.0 mg, 0.892 mmol, 65% yield); TLC Rf = 0.21 (hexane: EtOAc, 3:1); mp, 214.2&#8211;215.8 &#176;C. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#948; 8.56 (s, br, 1H, exch., -OH), 7.85 (d, J = 9.2 Hz, 1H, Ar), 7.62 (d, J = 7.5 Hz, 1H, Ar), 7.46 (s, br, 1H, exch., -NH), 7.35&#8211;7.22 (m, 2H, Ar), 6.76 (dd, J = 9.2, 2.4 Hz, 1H, Ar), 6.10 (d, J = 7.5 Hz, 1H, Ar), 2.65 (t, 2H, -CH<sub>2</sub>), 2.58 (s, 3H, 2-CH<sub>3</sub>), 1.89 (t, 2H, -CH<sub>2</sub>), 1.58&#8211;1.51 (m, 2H, -CH<sub>2</sub>), 1.45&#8211;1.38 (m, 2H, -CH<sub>2</sub>).Anal. Calcd. for C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>OS 0.19 (CH<sub>3</sub>)<sub>2</sub>CHOH 0.13 HCl: C, 68.59; H, 5.51; N, 11.13; S, 8.49. Found: C, 68.78; H, 5.30; N, 11.63; S, 8.87.</p><p><italic toggle="yes">N</italic>-(5-methoxynaphthalen-2-yl)-<italic toggle="yes">N</italic>,2-dimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidin-4-amine (<bold>13</bold>): Compound <bold>14</bold> (250 mg, 0.691 mmol) was dissolved in DMF (10 mL), followed by portion-wise addition of sodium hydride (60% in mineral oil) (28.0 mg, 0.691 mmol). Iodomethane (0.043 mL, 0.691 mmol) dissolved in 5 mL of DMF was added drop-wise to the suspension. The reaction was stirred for 2 h at room temperature. Silica gel was added to the solvent mixture, and a plug was prepared. A flash column chromatographic separation was performed using ethyl acetate-hexane as eluent to afford <bold>13</bold> as a yellow solid (153.56 mg, 57% yield); TLC Rf = 0.46 (hexane: EtOAc, 3:1); mp, 205.1&#8211;207.2 &#176;C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#948; 7.99 (d, J = 9.2 Hz, 1H, Ar), 7.32 (d, J = 7.8 Hz, 1H, Ar), 7.29&#8211;7.24 (m, 2H, Ar), 7.09 (dd, J = 9.1, 2.4 Hz, 1H, Ar), 6.82 (d, J = 7.5 Hz, 1H, Ar), 3.92 (s, 3H, -OCH<sub>3</sub>), 3.53 (s, 3H, N<sub>4</sub>-CH<sub>3</sub>), 2.69 (t, 2H, -CH<sub>2</sub>), 2.61 (s, 3H, 2-CH<sub>3</sub>), 1.87 (t, 2H, -CH<sub>2</sub>), 1.51&#8211;1.45 (m, 2H, -CH<sub>2</sub>), 1.40&#8211;1.32 (m, 2H, -CH<sub>2</sub>). Anal. Calcd. for C<sub>23</sub>H<sub>23</sub>N<sub>3</sub>OS: C, 70.92; H, 5.95; N, 10.78; S, 8.23. Found: C, 70.75; H, 6.11; N, 10.53; S, 7.95.</p></sec></sec><sec id="sec3dot2-molecules-27-00321"><title>3.2. Molecular Modeling</title><p>Docking of target compounds <bold>4</bold>&#8211;<bold>14</bold> was carried out in the colchicine site of tubulin (PDB: 6BS2, 2.65 &#197;). The crystal structure PDBs were obtained from the protein database. All docking procedures were performed using various modules of the Schr&#246;dinger Maestro suite (Schr&#246;dinger, LLC, New York, NY, USA, 2020&#8211;2) [<xref rid="B49-molecules-27-00321" ref-type="bibr">49</xref>]. The protein was optimized and prepared for docking using the Maestro Protein Preparation Wizard to assess bond order and add missing hydrogens, followed by energy minimization using the OPLS3e force field. Gaps in the protein structures were ignored, as they were far from the active site. The Maestro Induced-fit Grid Generation module was then used to define a 15 &#215; 15 &#215; 15 &#197; grid from the center of all the ligands. Ligands used in the computational docking study were built using the Maestro 2D Build module. The Maestro LigPrep module was then used to generate conformers of each compound subjected to energy minimization using the OPLS3e force field protocol. The resulting compounds were docked into the prepared protein using the Maestro Induced Fit Docking. Induced Fit Docking was performed with standard precision with flexible ligand sampling. A total of 20 initial poses were generated for each compound. Based on the pose score, the top 4 poses were selected and subjected to energy minimization using the OPLS3e force field. Finally, the top 2 poses per compound were generated and ranked according to the Glide score, which is an approximation of binding energy defined by receptor&#8211;ligand complex energies. The top pose was analyzed and presented in the Biological Evaluation and Discussion section. Docking scores are listed in <xref rid="app1-molecules-27-00321" ref-type="app">Table S1</xref> (<xref rid="app1-molecules-27-00321" ref-type="app">Supplementary Materials</xref>).</p></sec><sec id="sec3dot3-molecules-27-00321"><title>3.3. Biological Studies</title><sec id="sec3dot3dot1-molecules-27-00321"><title>3.3.1. Effects of Compounds on Cellular Microtubules</title><p>The effects of the compounds on cellular microtubules were evaluated in A-10 cells using indirect immunofluorescence microscopy. These cells were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). Cells were treated with the compounds of interest for 18 h, and the cells fixed with cold MeOH and microtubule structures were visualized using a &#946;-tubulin antibody (Sigma-Aldrich, St. Louis, MO, USA). The concentration that caused loss of 50% of the interphase microtubules was defined as the EC<sub>50</sub> and calculated as previously described [<xref rid="B52-molecules-27-00321" ref-type="bibr">52</xref>]. These values represent an average of at least three independent experiments.</p></sec><sec id="sec3dot3dot2-molecules-27-00321"><title>3.3.2. Sulforhodamine B (SRB) Assay</title><p>The antiproliferative and cytotoxic effects of the compounds in cancer cells were evaluated using the SRB assay [<xref rid="B53-molecules-27-00321" ref-type="bibr">53</xref>] as previously described [<xref rid="B54-molecules-27-00321" ref-type="bibr">54</xref>]. MDA-MB-435 cells were obtained from the Lombardi Cancer Center of Georgetown University (Washington, DC, USA). SK-OV-3 and HeLa cells were purchased from ATCC. Details about the generation of the SK-OV-3 MDR1-M6/6 and HeLa WT&#946;III cells were described previously [<xref rid="B54-molecules-27-00321" ref-type="bibr">54</xref>]. The IC<sub>50</sub> values represent an average of three independent experiments, each conducted using triplicate points.</p></sec><sec id="sec3dot3dot3-molecules-27-00321"><title>3.3.3. Quantitative Tubulin Studies</title><p>Bovine brain tubulin was purified as described previously [<xref rid="B55-molecules-27-00321" ref-type="bibr">55</xref>]. The tubulin assembly assay has been described in detail [<xref rid="B50-molecules-27-00321" ref-type="bibr">50</xref>]. Briefly, 1.0 mg/mL of tubulin (10 &#181;M) was preincubated for 15 min at 30 &#176;C in 0.8 M monosodium glutamate (pH of 2 M stock solution adjusted to 6.6 with HCl), varying compound concentrations and 4% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) DMSO as compound solvent. After the preincubation, the reaction mixtures were placed on ice and 0.4 mM GTP was added. The reaction mixtures were transferred to cuvettes at 0 &#176;C in a recording spectrophotometer equipped with an electronic temperature controller. After baselines were established, the temperature was elevated over about 30 s to 30 &#176;C, and changes in turbidity were monitored at 350 nm for 20 min. The compound concentration that caused a 50% reduction in increase in turbidity, interpolated from the values obtained with defined compound concentrations, was defined as the IC<sub>50</sub> value. The assay to measure inhibition of [<sup>3</sup>H]colchicine binding was described in detail previously [<xref rid="B56-molecules-27-00321" ref-type="bibr">56</xref>]. Briefly, 0.1 mg/mL (1.0 &#181;M) tubulin was incubated at 37 &#176;C with 5.0 &#181;M [3H]colchicine and potential inhibitors at 5.0 &#181;M. Incubation was for 10 min, at which point the reaction had reached 40&#8211;60% of the maximum colchicine that can be bound in reaction mixtures without inhibitor. The [<sup>3</sup>H]colchicine was a product of PerkinElmer, USA. CA-4 was a generous gift of Dr. G. R. Pettit, Arizona State University.</p></sec><sec id="sec3dot3dot4-molecules-27-00321"><title>3.3.4. Cell Culture</title><p>HeLa, A-10, SK-OV-3, and SK-OV-3 MDR1-M6/6 cells were grown in Basal Medium Eagle (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% FBS (Hyclone, GE Life Sciences, Logan, UT, USA) 1% GlutaMAX (Gibco, Life Technologies, Waltham, MA, USA) and 50 &#181;g/mL gentamycin (Life Technologies, USA). HeLa WT&#946;III cells were grown in Dulbecco&#8217;s Modified Eagle Medium (Life Technologies) supplemented with 10% FBS and 50 &#181;g/mL gentamycin. MDA-MB-435 cells were maintained in Improved Minimum Essential Medium (Life Technologies) supplemented with 10% FBS and 25 &#181;g/mL gentamycin. All cells were grown at 37 &#176;C in a humidified environment with 5% CO<sub>2</sub>.</p></sec><sec id="sec3dot3dot5-molecules-27-00321"><title>3.3.5. MDA-MB-435 Xenograft Model</title><p>MDA-MB-435 tumor fragments were implanted s.c. into the flanks of female nude mice. Once tumors reached ~200 mm<sup>3</sup>, mice were injected i.p. with compound <bold>4</bold> (75 mg/kg) or paclitaxel (15 mg/kg) 3 times a week. Compound <bold>4</bold> was dissolved in a 50:50 Cremophor EL/DMSO mixture and further dissolved in PBS for a final concentration of 10:10:80 Cremophor EL:DMSO:PBS (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>). Paclitaxel was dissolved in a 50:50 Cremophor EL/ EtOH mixture and further dissolved in PBS for a final solvent concentration of less than 5% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) Cremophor/EtOH in PBS. Tumor volumes and mouse weights were measured 2&#8211;3 times a week. A two-way ANOVA with Dunnett&#8217;s post-hoc tests including all treatment groups in the trial was used to determine significant differences in tumor volumes between drug-treated and untreated control groups on each measurement day. These animal studies were performed at the University of Texas Health Science Center in San Antonio in compliance with an approved Institutional Animal Care and Use protocol.</p></sec></sec></sec><sec sec-type="conclusions" id="sec4-molecules-27-00321"><title>4. Conclusions</title><p>A series of 11 novel 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidines were designed, synthesized and assessed as MTAs. Several of these analogues were significantly more potent than the lead compounds and circumvented drug resistance mediated by Pgp and &#946;III-tubulin. Compound <bold>4</bold> showed statistically significant antitumor effects in an in vivo xenograft model (MDA-MB-435). This study corroborated our molecular modeling predictions, which suggested structural variations to improve binding at the CS to afford better MTAs for the potential treatment of cancer. Compound <bold>4</bold> is a candidate for further evaluation in preclinical studies to evaluate its antitumor efficacy.</p></sec></body><back><ack><title>Acknowledgments</title><p>We acknowledge the National Cancer Institute Developmental Therapeutics Program for performing the in vitro evaluation in the NCI 60-cell line panel.</p></ack><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-molecules-27-00321"><title>Supplementary Materials</title><p>Table S1: Docking scores; Figure S1: Superposition of 6BS2 pyrimidine ligand with compound <bold>4</bold>.</p><supplementary-material id="molecules-27-00321-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-27-00321-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conception and design, A.G. and S.L.M.; development of methodology, F.I., A.D., X.Z. (Xin Zhang), X.Z. (Xilin Zhou) and T.M.Q.; acquisition of data (provided animals, provided facilities, etc.), A.J.R. and E.H.; analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis), A.J.R. and T.M.Q.; writing&#8212;review and/or revision of the manuscript, F.I.; administrative&#8212;technical or material support (reporting or organizing data, constructing databases), F.I.; study supervision, A.G. and S.L.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was supported, in part, by a grant from the National Institutes of Health, National Cancer Institute (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="CA142868">CA142868</ext-link> (to A.G., S.L.M.)); by the Greehey Distinguished Chair in Targeted Molecular Therapeutics (to S.L.M.), Duquesne University Adrian Van Kaam Chair in Scholarly Excellence (to A.G.); and by an NSF equipment grant for NMR instrumentation (NMR: CHE 0614785). This research was supported in part by the Developmental Therapeutics Program in the Division of Cancer Treatment and Diagnosis of the National Cancer Institute, which includes federal funds under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no competing financial interest.</p></notes><notes><title>Sample Availability</title><p>Samples of the compounds are not available from the authors.</p></notes><ref-list><title>References</title><ref id="B1-molecules-27-00321"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>L.</given-names></name></person-group><article-title>Microtubules as a target for anticancer drugs</article-title><source>Nat. Rev. Cancer</source><year>2004</year><volume>4</volume><fpage>253</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1038/nrc1317</pub-id><pub-id pub-id-type="pmid">15057285</pub-id></element-citation></ref><ref id="B2-molecules-27-00321"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumontet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>M.A.</given-names></name></person-group><article-title>Microtubule-binding agents: A dynamic field of cancer therapeutics</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>790</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1038/nrd3253</pub-id><pub-id pub-id-type="pmid">20885410</pub-id><pub-id pub-id-type="pmcid">PMC3194401</pub-id></element-citation></ref><ref id="B3-molecules-27-00321"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Field</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kanakkanthara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.H.</given-names></name></person-group><article-title>Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</article-title><source>Bioorganic Med. Chem.</source><year>2014</year><volume>22</volume><fpage>5050</fpage><lpage>5059</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2014.02.035</pub-id><pub-id pub-id-type="pmid">24650703</pub-id></element-citation></ref><ref id="B4-molecules-27-00321"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Forges</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bouissou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>F.</given-names></name></person-group><article-title>Interplay between microtubule dynamics and intracellular organization</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2012</year><volume>44</volume><fpage>266</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2011.11.009</pub-id><pub-id pub-id-type="pmid">22108200</pub-id></element-citation></ref><ref id="B5-molecules-27-00321"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaul</surname><given-names>R.</given-names></name><name name-style="western"><surname>Risinger</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Mooberry</surname><given-names>S.L.</given-names></name></person-group><article-title>Microtubule-Targeting Drugs: More than Antimitotics</article-title><source>J. Nat. Prod.</source><year>2019</year><volume>82</volume><fpage>680</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.9b00105</pub-id><pub-id pub-id-type="pmid">30835122</pub-id></element-citation></ref><ref id="B6-molecules-27-00321"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinmetz</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Prota</surname><given-names>A.E.</given-names></name></person-group><article-title>Microtubule-Targeting Agents: Strategies to Hijack the Cytoskeleton</article-title><source>Trends Cell Biol.</source><year>2018</year><volume>28</volume><fpage>776</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2018.05.001</pub-id><pub-id pub-id-type="pmid">29871823</pub-id></element-citation></ref><ref id="B7-molecules-27-00321"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthew</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.-Y.</given-names></name><name name-style="western"><surname>Ratnayake</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fermaintt</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Lucena-Agell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bonato</surname><given-names>F.</given-names></name><name name-style="western"><surname>Prota</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>J.F.</given-names></name><etal/></person-group><article-title>Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2021</year><volume>118</volume><fpage>e2021847118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2021847118</pub-id><pub-id pub-id-type="pmid">33619102</pub-id><pub-id pub-id-type="pmcid">PMC7936326</pub-id></element-citation></ref><ref id="B8-molecules-27-00321"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohena</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Mooberry</surname><given-names>S.L.</given-names></name></person-group><article-title>Recent progress with microtubule stabilizers: New compounds, binding modes and cellular activities</article-title><source>Nat. Prod. Rep.</source><year>2014</year><volume>31</volume><fpage>335</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1039/C3NP70092E</pub-id><pub-id pub-id-type="pmid">24481420</pub-id><pub-id pub-id-type="pmcid">PMC4167679</pub-id></element-citation></ref><ref id="B9-molecules-27-00321"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yee</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Risinger</surname><given-names>A.L.</given-names></name></person-group><article-title>Taccalonolide microtubule stabilizers</article-title><source>Prog. Chem. Org. Nat. Prod.</source><year>2020</year><volume>112</volume><fpage>183</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">33306174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-030-52966-6_3</pub-id><pub-id pub-id-type="pmcid">PMC7800047</pub-id></element-citation></ref><ref id="B10-molecules-27-00321"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Field</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Pera</surname><given-names>B.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Canales</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zurwerra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Trigili</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Salarichs</surname><given-names>J.</given-names></name><name name-style="western"><surname>Matesanz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kanakkanthara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wakefieldet</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Zampanolide, a potent new microtubule-stabilizing agent, covalently reacts with the taxane luminal site in tubulin &#945;,&#946;-heterodimers and microtubules</article-title><source>Chem. Biol.</source><year>2012</year><volume>19</volume><fpage>686</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2012.05.008</pub-id><pub-id pub-id-type="pmid">22726683</pub-id><pub-id pub-id-type="pmcid">PMC3383615</pub-id></element-citation></ref><ref id="B11-molecules-27-00321"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Towle</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saxton</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reardon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Kuznetsov</surname><given-names>G.</given-names></name><name name-style="western"><surname>Johannes</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Tremblay</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent</article-title><source>Anticancer Res.</source><year>2007</year><volume>27</volume><fpage>1509</fpage><lpage>1518</lpage><pub-id pub-id-type="pmid">17595769</pub-id></element-citation></ref><ref id="B12-molecules-27-00321"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanakkanthara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Northcote</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.H.</given-names></name></person-group><article-title>Peloruside A: A lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune disease</article-title><source>Nat. Prod. Rep.</source><year>2016</year><volume>33</volume><fpage>549</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1039/C5NP00146C</pub-id><pub-id pub-id-type="pmid">26867978</pub-id></element-citation></ref><ref id="B13-molecules-27-00321"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prota</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Bargsten</surname><given-names>K.</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cuevas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liniger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neuhaus</surname><given-names>C.</given-names></name><name name-style="western"><surname>Andreu</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Altmann</surname><given-names>K.-H.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>M.O.</given-names></name></person-group><article-title>A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>13817</fpage><lpage>13821</lpage><pub-id pub-id-type="doi">10.1073/pnas.1408124111</pub-id><pub-id pub-id-type="pmid">25114240</pub-id><pub-id pub-id-type="pmcid">PMC4183314</pub-id></element-citation></ref><ref id="B14-molecules-27-00321"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prota</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Setter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Waight</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Bargsten</surname><given-names>K.</given-names></name><name name-style="western"><surname>Murga</surname><given-names>J.</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>M.O.</given-names></name></person-group><article-title>Pironetin Binds Covalently to &#945;Cys316 and Perturbs a Major Loop and Helix of &#945;-Tubulin to Inhibit Microtubule Formation</article-title><source>J. Mol. Biol.</source><year>2016</year><volume>428</volume><fpage>2981</fpage><lpage>2988</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2016.06.023</pub-id><pub-id pub-id-type="pmid">27395016</pub-id></element-citation></ref><ref id="B15-molecules-27-00321"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dybdal-Hargreaves</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Risinger</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Mooberry</surname><given-names>S.L.</given-names></name></person-group><article-title>Eribulin mesylate: Mechanism of action of a unique microtubule-targeting agent</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>2445</fpage><lpage>2452</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-3252</pub-id><pub-id pub-id-type="pmid">25838395</pub-id><pub-id pub-id-type="pmcid">PMC4812567</pub-id></element-citation></ref><ref id="B16-molecules-27-00321"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Arnst</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>1281</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22081281</pub-id><pub-id pub-id-type="pmcid">PMC6152078</pub-id><pub-id pub-id-type="pmid">28763044</pub-id></element-citation></ref><ref id="B17-molecules-27-00321"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Burlingame</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Okcu</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>N.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>H.V.</given-names></name><name name-style="western"><surname>Egler</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>David</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Vasudevan</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</article-title><source>Mol. Cancer Ther.</source><year>2009</year><volume>8</volume><fpage>2086</fpage><lpage>2095</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-0366</pub-id><pub-id pub-id-type="pmid">19671735</pub-id></element-citation></ref><ref id="B18-molecules-27-00321"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duran</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Francisco</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Coller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brassard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vrignaud</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sikic</surname><given-names>B.I.</given-names></name></person-group><article-title>Mechanisms of Resistance to Cabazitaxel</article-title><source>Mol. Cancer Ther.</source><year>2014</year><volume>14</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0155</pub-id><pub-id pub-id-type="pmid">25416788</pub-id><pub-id pub-id-type="pmcid">PMC4447706</pub-id></element-citation></ref><ref id="B19-molecules-27-00321"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Overexpression of Class III &#946;-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer</article-title><source>BMC Cancer</source><year>2015</year><volume>15</volume><elocation-id>536</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-015-1553-x</pub-id><pub-id pub-id-type="pmid">26198101</pub-id><pub-id pub-id-type="pmcid">PMC4511538</pub-id></element-citation></ref><ref id="B20-molecules-27-00321"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>Y.-T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.-N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.-P.</given-names></name></person-group><article-title>Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments</article-title><source>Curr. Med. Chem.</source><year>2015</year><volume>22</volume><fpage>1348</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.2174/0929867322666150114163732</pub-id><pub-id pub-id-type="pmid">25620094</pub-id></element-citation></ref><ref id="B21-molecules-27-00321"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>D.D.</given-names></name></person-group><article-title>An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site</article-title><source>Pharm. Res.</source><year>2012</year><volume>29</volume><fpage>2943</fpage><lpage>2971</lpage><pub-id pub-id-type="doi">10.1007/s11095-012-0828-z</pub-id><pub-id pub-id-type="pmid">22814904</pub-id><pub-id pub-id-type="pmcid">PMC3667160</pub-id></element-citation></ref><ref id="B22-molecules-27-00321"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLoughlin</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>O&#8242;Boyle</surname><given-names>N.M.</given-names></name></person-group><article-title>Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review</article-title><source>Pharmaceuticals</source><year>2020</year><volume>13</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.3390/ph13010008</pub-id><pub-id pub-id-type="pmid">31947889</pub-id><pub-id pub-id-type="pmcid">PMC7168938</pub-id></element-citation></ref><ref id="B23-molecules-27-00321"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Echteld</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wechalekar</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Schlesinger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Buchbinder</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aletaha</surname><given-names>D.</given-names></name></person-group><article-title>Colchicine for acute gout</article-title><source>Cochrane Database Syst. Rev.</source><year>2014</year><volume>15</volume><fpage>CD006190</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD006190.pub2</pub-id><pub-id pub-id-type="pmid">25123076</pub-id></element-citation></ref><ref id="B24-molecules-27-00321"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stengel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Leese</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Purohit</surname><given-names>A.</given-names></name></person-group><article-title>Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents</article-title><source>Br. J. Cancer</source><year>2010</year><volume>102</volume><fpage>316</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605489</pub-id><pub-id pub-id-type="pmid">20029418</pub-id><pub-id pub-id-type="pmcid">PMC2816659</pub-id></element-citation></ref><ref id="B25-molecules-27-00321"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devambatla</surname><given-names>R.K.V.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zaware</surname><given-names>N.</given-names></name><name name-style="western"><surname>Choudhary</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mooberry</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Gangjee</surname><given-names>A.</given-names></name></person-group><article-title>Design, synthesis, and structure-activity relationships of pyrimido[4,5-b]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2017</year><volume>27</volume><fpage>3423</fpage><lpage>3430</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2017.05.085</pub-id><pub-id pub-id-type="pmid">28610978</pub-id><pub-id pub-id-type="pmcid">PMC5603926</pub-id></element-citation></ref><ref id="B26-molecules-27-00321"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gangjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zaware</surname><given-names>N.</given-names></name><name name-style="western"><surname>Devambatla</surname><given-names>R.K.V.</given-names></name><name name-style="western"><surname>Raghavan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Westbrook</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Dybdal-Hargreaves</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mooberry</surname><given-names>S.L.</given-names></name></person-group><article-title>Synthesis of N4-(substituted phenyl)-N4-alkyl/desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines and identification of new microtubule disrupting compounds that are effective against multidrug resistant cells</article-title><source>Bioorg. Med. Chem.</source><year>2012</year><volume>21</volume><fpage>891</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2012.12.010</pub-id><pub-id pub-id-type="pmid">23332369</pub-id><pub-id pub-id-type="pmcid">PMC3572549</pub-id></element-citation></ref><ref id="B27-molecules-27-00321"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Choudhary</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mooberry</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Gangjee</surname><given-names>A.</given-names></name></person-group><article-title>Structure based drug design and in vitro metabolism study: Discovery of N-(4-methylthiophenyl)-N,2-dimethyl-cyclopenta[d]pyrimidine as a potent microtubule targeting agent</article-title><source>Bioorg. Med. Chem.</source><year>2018</year><volume>26</volume><fpage>2437</fpage><lpage>2451</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2018.04.010</pub-id><pub-id pub-id-type="pmid">29655610</pub-id><pub-id pub-id-type="pmcid">PMC5967629</pub-id></element-citation></ref><ref id="B28-molecules-27-00321"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Taisan</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Al-Hazimi</surname><given-names>H.M.A.</given-names></name><name name-style="western"><surname>Al-Shihry</surname><given-names>S.S.</given-names></name></person-group><article-title>Synthesis, Characterization and Biological Studies of Some Novel Thieno[2,3-<italic toggle="yes">d</italic>]pyrimidines</article-title><source>Molecules</source><year>2010</year><volume>15</volume><fpage>3932</fpage><lpage>3957</lpage><pub-id pub-id-type="doi">10.3390/molecules15063932</pub-id><pub-id pub-id-type="pmid">20657418</pub-id><pub-id pub-id-type="pmcid">PMC6257563</pub-id></element-citation></ref><ref id="B29-molecules-27-00321"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aly</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ishak</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ramadan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Germoush</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>El-Emary</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Al-Muaikel</surname><given-names>N.S.</given-names></name></person-group><article-title>Recent Report on Thieno[2,3-<italic toggle="yes">d</italic>]pyrimidines. Their Preparation Including Microwave and Their Utilities in Fused Heterocycles Synthesis</article-title><source>J. Heterocycl. Chem.</source><year>2013</year><volume>50</volume><fpage>451</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1002/jhet.1118</pub-id></element-citation></ref><ref id="B30-molecules-27-00321"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chitikina</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Buddiga</surname><given-names>P.</given-names></name><name name-style="western"><surname>Deb</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Mailavaram</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Venugopala</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Al-Jaidi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kar</surname><given-names>S.</given-names></name></person-group><article-title>Synthesis and anthelmintic activity of some novel (E)-2-methyl/propyl-4-(2-(substitutedbenzylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidines</article-title><source>Med. Chem. Res.</source><year>2020</year><volume>29</volume><fpage>1600</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1007/s00044-020-02586-5</pub-id></element-citation></ref><ref id="B31-molecules-27-00321"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmetwally</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Saied</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Eissa</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Elkaeed</surname><given-names>E.B.</given-names></name></person-group><article-title>Design, synthesis and anticancer evaluation of thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers</article-title><source>Bioorg. Chem.</source><year>2019</year><volume>88</volume><fpage>102944</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2019.102944</pub-id><pub-id pub-id-type="pmid">31051400</pub-id></element-citation></ref><ref id="B32-molecules-27-00321"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>C.</given-names></name></person-group><article-title>5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine derivatives as inhibitors of full-length ROR&#947;t</article-title><source>Bioorg. Chem.</source><year>2019</year><volume>90</volume><fpage>103077</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2019.103077</pub-id><pub-id pub-id-type="pmid">31323598</pub-id></element-citation></ref><ref id="B33-molecules-27-00321"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahapatra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>T.</given-names></name></person-group><article-title>Pyrimidine: A review on anticancer activity with key emphasis on SAR</article-title><source>Future J. Pharm. Sci.</source><year>2021</year><volume>7</volume><fpage>123</fpage><pub-id pub-id-type="doi">10.1186/s43094-021-00274-8</pub-id></element-citation></ref><ref id="B34-molecules-27-00321"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raza</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Legac</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ataur Rahman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Manzoor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Hoda</surname><given-names>N.</given-names></name></person-group><article-title>Design, synthesis, crystal structure and anti-plasmodial evaluation of tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine derivatives</article-title><source>RSC Med. Chem.</source><year>2021</year><volume>12</volume><fpage>970</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1039/D1MD00038A</pub-id><pub-id pub-id-type="pmid">34223162</pub-id><pub-id pub-id-type="pmcid">PMC8221264</pub-id></element-citation></ref><ref id="B35-molecules-27-00321"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavase</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Mane</surname><given-names>D.V.</given-names></name></person-group><article-title>Synthesis and anticancer activities of novel (tetrahydrobenzo [4,5] thieno [2,3-<italic toggle="yes">d</italic>] pyrimidine-4-yl)-pyrolidine-2-carboxylic acid derivatives</article-title><source>Med. Chem. Res.</source><year>2016</year><volume>25</volume><fpage>2380</fpage><lpage>2391</lpage><pub-id pub-id-type="doi">10.1007/s00044-016-1692-x</pub-id></element-citation></ref><ref id="B36-molecules-27-00321"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;deboscq</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gravier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Casadebaig</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gissot</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Giorgi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ichas</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cambar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pometan</surname><given-names>J.-P.</given-names></name></person-group><article-title>Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells</article-title><source>Eur. J. Med. Chem.</source><year>2010</year><volume>45</volume><fpage>2473</fpage><lpage>2479</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2010.02.032</pub-id><pub-id pub-id-type="pmid">20219270</pub-id></element-citation></ref><ref id="B37-molecules-27-00321"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharaky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kamel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Omran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rageh</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Abouzid</surname><given-names>K.A.M.</given-names></name><name name-style="western"><surname>Shouman</surname><given-names>S.A.</given-names></name></person-group><article-title>Design, synthesis and biological evaluation of a new thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine-based urea derivative with potential antitumor activity against tamoxifen sensitive and resistant breast cancer cell lines</article-title><source>J. Enzym. Inhib. Med. Chem.</source><year>2020</year><volume>35</volume><fpage>1641</fpage><lpage>1656</lpage><pub-id pub-id-type="doi">10.1080/14756366.2020.1804383</pub-id><pub-id pub-id-type="pmcid">PMC7470147</pub-id><pub-id pub-id-type="pmid">32781854</pub-id></element-citation></ref><ref id="B38-molecules-27-00321"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name></person-group><article-title>5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-<italic toggle="yes">d</italic>]pyrimidine derivative attenuates lupus nephritis with less effect to thymocyte development</article-title><source>Immunol. Res.</source><year>2021</year><volume>69</volume><fpage>378</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1007/s12026-021-09204-5</pub-id><pub-id pub-id-type="pmid">34219199</pub-id></element-citation></ref><ref id="B39-molecules-27-00321"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>M.-H.</given-names></name></person-group><article-title>Theoretical Calculation of Hydrogen-Bonding Strength for Drug Molecules</article-title><source>J. Chem. Theory Comput.</source><year>2006</year><volume>2</volume><fpage>863</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1021/ct0600262</pub-id><pub-id pub-id-type="pmid">26626693</pub-id></element-citation></ref><ref id="B40-molecules-27-00321"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritchie</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Macdonald</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Pickett</surname><given-names>S.D.</given-names></name></person-group><article-title>The impact of aromatic ring count on compound developability: Further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</article-title><source>Drug Discov. Today</source><year>2011</year><volume>16</volume><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2010.11.014</pub-id><pub-id pub-id-type="pmid">21129497</pub-id></element-citation></ref><ref id="B41-molecules-27-00321"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Britten</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Denis</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Drengler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Siu</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Duchin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rowinsky</surname><given-names>E.K.</given-names></name></person-group><article-title>Oral paclitaxel and concurrent cyclosporin A: Targeting clinically relevant systemic exposure to paclitaxel</article-title><source>Clin. Cancer Res.</source><year>2000</year><volume>6</volume><fpage>3459</fpage><lpage>3468</lpage><pub-id pub-id-type="pmid">10999729</pub-id></element-citation></ref><ref id="B42-molecules-27-00321"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blundell</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Packer</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Almond</surname><given-names>A.</given-names></name></person-group><article-title>Quantification of free ligand conformational preferences by NMR and their relationship to the bioactive conformation</article-title><source>Bioorg. Med. Chem.</source><year>2013</year><volume>21</volume><fpage>4976</fpage><lpage>4987</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2013.06.056</pub-id><pub-id pub-id-type="pmid">23886813</pub-id><pub-id pub-id-type="pmcid">PMC3744816</pub-id></element-citation></ref><ref id="B43-molecules-27-00321"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arnst</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.-B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>White</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy</article-title><source>J. Med. Chem.</source><year>2018</year><volume>61</volume><fpage>1704</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01858</pub-id><pub-id pub-id-type="pmid">29406710</pub-id><pub-id pub-id-type="pmcid">PMC5912893</pub-id></element-citation></ref><ref id="B44-molecules-27-00321"><label>44.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Schr&#1255;dinger</collab></person-group><source>Release 2020-2: Maestro, Schrodinger</source><publisher-name>Schr&#1255;dinger LLC</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B45-molecules-27-00321"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gangjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pavana</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Ihnat</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Thorpe</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Disch</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Bastian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bailey-Downs</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>R.</given-names></name></person-group><article-title>Discovery of Antitubulin Agents with Antiangiogenic Activity as Single Entities with Multitarget Chemotherapy Potential</article-title><source>ACS Med. Chem. Lett.</source><year>2014</year><volume>5</volume><fpage>480</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1021/ml4004793</pub-id><pub-id pub-id-type="pmid">24900865</pub-id><pub-id pub-id-type="pmcid">PMC4027584</pub-id></element-citation></ref><ref id="B46-molecules-27-00321"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>F.</given-names></name><name name-style="western"><surname>Quadery</surname><given-names>T.M.</given-names></name></person-group><article-title>Therapeutic potential, synthesis, patent evaluation and SAR studies of thieno[3,2-<italic toggle="yes">d</italic>]pyrimidine derivatives: Recent updates</article-title><source>Curr. Drug Targets</source><year>2021</year><volume>22</volume><fpage>1944</fpage><lpage>1963</lpage><pub-id pub-id-type="doi">10.2174/1389450122666210526094047</pub-id><pub-id pub-id-type="pmid">34042033</pub-id></element-citation></ref><ref id="B47-molecules-27-00321"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>F.</given-names></name><name name-style="western"><surname>Quadery</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Luckett-Chastain</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ihnat</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gangjee</surname><given-names>A.</given-names></name></person-group><article-title>Novel pyrazolo[4,3-d]pyrimidine microtubule targeting agents (MTAs): Synthesis, structure&#8211;activity relationship, in vitro and in vivo evaluation as antitumor agents</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2021</year><volume>41</volume><fpage>127923</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2021.127923</pub-id><pub-id pub-id-type="pmid">33705908</pub-id><pub-id pub-id-type="pmcid">PMC8113149</pub-id></element-citation></ref><ref id="B48-molecules-27-00321"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Quadery</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Luckett-Chastain</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Ihnat</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mooberry</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Gangjee</surname><given-names>A.</given-names></name></person-group><article-title>The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity</article-title><source>Bioorg. Med. Chem.</source><year>2020</year><volume>29</volume><fpage>115887</fpage><pub-id pub-id-type="doi">10.1016/j.bmc.2020.115887</pub-id><pub-id pub-id-type="pmid">33310545</pub-id><pub-id pub-id-type="pmcid">PMC7875120</pub-id></element-citation></ref><ref id="B49-molecules-27-00321"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>F.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dekhne</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Matherly</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Gangjee</surname><given-names>A.</given-names></name></person-group><article-title>Design, synthesis and biological evaluation of novel pyrrolo[2,3-<italic toggle="yes">d</italic>]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier</article-title><source>Bioorg. Med. Chem.</source><year>2020</year><volume>28</volume><fpage>115544</fpage><pub-id pub-id-type="doi">10.1016/j.bmc.2020.115544</pub-id><pub-id pub-id-type="pmid">32503687</pub-id><pub-id pub-id-type="pmcid">PMC7327796</pub-id></element-citation></ref><ref id="B50-molecules-27-00321"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamel</surname><given-names>E.</given-names></name></person-group><article-title>Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</article-title><source>Cell Biochem. Biophys.</source><year>2003</year><volume>38</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1385/CBB:38:1:1</pub-id><pub-id pub-id-type="pmid">12663938</pub-id></element-citation></ref><ref id="B51-molecules-27-00321"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bogolubsky</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Ryabukhin</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Plaskon</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Stetsenko</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Volochnyuk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tolmachev</surname><given-names>A.A.</given-names></name></person-group><article-title>Dry HCl in Parallel Synthesis of Fused Pyrimidin-4-ones</article-title><source>J. Comb. Chem.</source><year>2008</year><volume>10</volume><fpage>858</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1021/cc800074t</pub-id><pub-id pub-id-type="pmid">18767818</pub-id></element-citation></ref><ref id="B52-molecules-27-00321"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>L.</given-names></name><name name-style="western"><surname>Robb</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chavda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Babu</surname><given-names>B.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Risinger</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Mooberry</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Design, Synthesis, and Biological Evaluations of 2,5-Diaryl-2,3-<italic toggle="yes">d</italic>ihydro-1,3,4-oxadiazoline Analogs of Combretastatin-A4</article-title><source>J. Med. Chem.</source><year>2009</year><volume>53</volume><fpage>325</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1021/jm901268n</pub-id><pub-id pub-id-type="pmcid">PMC2810428</pub-id><pub-id pub-id-type="pmid">19894742</pub-id></element-citation></ref><ref id="B53-molecules-27-00321"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skehan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Storeng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scudiero</surname><given-names>D.</given-names></name><name name-style="western"><surname>Monks</surname><given-names>A.</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vistica</surname><given-names>D.</given-names></name><name name-style="western"><surname>Warren</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Bokesch</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kenney</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>M.R.</given-names></name></person-group><article-title>New colorimetric cytotoxicity assay for anticancer-drug screening</article-title><source>J. Natl. Cancer Inst.</source><year>1990</year><volume>82</volume><fpage>1107</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1093/jnci/82.13.1107</pub-id><pub-id pub-id-type="pmid">2359136</pub-id></element-citation></ref><ref id="B54-molecules-27-00321"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Risinger</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Polin</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Helms</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Leboeuf</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Joe</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Hopper-Borge</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ludue&#241;a</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Kruh</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Mooberry</surname><given-names>S.L.</given-names></name></person-group><article-title>The Taccalonolides: Microtubule Stabilizers That Circumvent Clinically Relevant Taxane Resistance Mechanisms</article-title><source>Cancer Res.</source><year>2008</year><volume>68</volume><fpage>8881</fpage><lpage>8888</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2037</pub-id><pub-id pub-id-type="pmid">18974132</pub-id><pub-id pub-id-type="pmcid">PMC2727482</pub-id></element-citation></ref><ref id="B55-molecules-27-00321"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.M.</given-names></name></person-group><article-title>Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles</article-title><source>Biochemistry</source><year>1984</year><volume>23</volume><fpage>4173</fpage><lpage>4184</lpage><pub-id pub-id-type="doi">10.1021/bi00313a026</pub-id><pub-id pub-id-type="pmid">6487596</pub-id></element-citation></ref><ref id="B56-molecules-27-00321"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verdier-Pinard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>H.-D.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marquez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nagle</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Nambu</surname><given-names>M.</given-names></name><name name-style="western"><surname>White</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Falck</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Gerwick</surname><given-names>W.H.</given-names></name><etal/></person-group><article-title>Structure-Activity Analysis of the Interaction of Curacin A, the Potent Colchicine Site Antimitotic Agent, with Tubulin and Effects of Analogs on the Growth of MCF-7 Breast Cancer Cells</article-title><source>Mol. Pharmacol.</source><year>1998</year><volume>53</volume><fpage>62</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1124/mol.53.1.62</pub-id><pub-id pub-id-type="pmid">9443933</pub-id></element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Schemes and Tables</title><fig position="float" id="molecules-27-00321-f001" orientation="portrait"><label>Figure 1</label><caption><p>Representative MTAs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-27-00321-g001.jpg"/></fig><fig position="float" id="molecules-27-00321-f002" orientation="portrait"><label>Figure 2</label><caption><p>Structures and activities of Lead compounds <bold>1&#8211;3</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-27-00321-g002.jpg"/></fig><fig position="float" id="molecules-27-00321-f003" orientation="portrait"><label>Figure 3</label><caption><p>Systematic incorporation of structural strategies to restrict the rotation around bonds a and b.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-27-00321-g003.jpg"/></fig><fig position="float" id="molecules-27-00321-f004" orientation="portrait"><label>Figure 4</label><caption><p>(<bold>a</bold>) Docked pose of compound <bold>4</bold> (cyan) and colchicine (pink) in the CS (PDB: 6BS2, 2.65 &#197;) [<xref rid="B43-molecules-27-00321" ref-type="bibr">43</xref>] in Maestro 2020-2 (docked score of compound <bold>4</bold> was &#8722;10.89 kcal/mol.); (<bold>b</bold>) structures of <bold>4</bold> and colchicine.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-27-00321-g004.jpg"/></fig><fig position="float" id="molecules-27-00321-sch001" orientation="portrait"><object-id pub-id-type="pii">molecules-27-00321-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Synthesis of intermediates 20&#8211;<bold>22</bold> from cyclohexanone.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-27-00321-sch001.jpg"/></fig><fig position="float" id="molecules-27-00321-sch002" orientation="portrait"><object-id pub-id-type="pii">molecules-27-00321-sch002_Scheme 2</object-id><label>Scheme 2</label><caption><p>Synthesis of intermediate <bold>26</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-27-00321-sch002.jpg"/></fig><fig position="float" id="molecules-27-00321-sch003" orientation="portrait"><object-id pub-id-type="pii">molecules-27-00321-sch003_Scheme 3</object-id><label>Scheme 3</label><caption><p>Synthesis of target compounds <bold>4</bold>&#8211;<bold>6</bold>, <bold>7</bold>, <bold>9</bold>, <bold>11</bold>, <bold>12</bold> and <bold>14</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-27-00321-sch003.jpg"/></fig><fig position="float" id="molecules-27-00321-sch004" orientation="portrait"><object-id pub-id-type="pii">molecules-27-00321-sch004_Scheme 4</object-id><label>Scheme 4</label><caption><p>Synthesis of target compounds <bold>8</bold>, <bold>10</bold> and <bold>13</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-27-00321-sch004.jpg"/></fig><fig position="float" id="molecules-27-00321-f005" orientation="portrait"><label>Figure 5</label><caption><p>Effects of <bold>4</bold> and paclitaxel on the growth of MDA-MB-435 tumors. MDA-MB-435 tumors were implanted into the flanks of nude mice and allowed to grow until they reached a volume of ~200 mm<sup>3</sup>. The mice were treated i.p. with <bold>4</bold> (75 mg/kg) or paclitaxel (15 mg/kg) three times a week. Tumor volumes and mouse weights were measured 2&#8211;3 times a week. Statistical significance was evaluated by two-way ANOVA (time vs. drug) with Dunnett&#8217;s post-hoc tests. A statistically significant difference in tumor volume was detected on day 14 between mice treated with <bold>4</bold> (* <italic toggle="yes">p</italic> = 0.0384) and untreated control tumors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-27-00321-g005.jpg"/></fig><table-wrap position="float" id="molecules-27-00321-t001" orientation="portrait"><object-id pub-id-type="pii">molecules-27-00321-t001_Table 1</object-id><label>Table 1</label><caption><p>Synthesized compounds <bold>4</bold>&#8211;<bold>14</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-27-00321-i001.jpg"/><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound No.</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub></th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">R<sub>2</sub></th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NH<sub>2</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-27-00321-i002.jpg"/>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>5</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NH<sub>2</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-27-00321-i003.jpg"/>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NH<sub>2</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-27-00321-i004.jpg"/>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-27-00321-i005.jpg"/>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>8</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-27-00321-i006.jpg"/>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>9</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-27-00321-i007.jpg"/>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>10</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-27-00321-i008.jpg"/>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>11</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-27-00321-i009.jpg"/>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>12</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-27-00321-i010.jpg"/>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>13</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-27-00321-i011.jpg"/>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>14</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-27-00321-i012.jpg"/>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="molecules-27-00321-t002" orientation="portrait"><object-id pub-id-type="pii">molecules-27-00321-t002_Table 2</object-id><label>Table 2</label><caption><p>Antiproliferative and microtubule depolymerization effects.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound No</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> &#177; SD in MDA-435 Cells (nM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EC<sub>50</sub> for Microtubule Depolymerization in A-10 Cells (nM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EC<sub>50</sub>/IC<sub>50</sub> Ratio</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>1</bold>
<sup>a</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.7 &#177; 1.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">130</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>2</bold>
<sup>b</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.1 &#177; 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>3</bold>
<sup>c</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">130 &#177; 7.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.0 &#177; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>5</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.6 &#177; 5.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.6 &#177; 11.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">121</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.8 &#177; 5.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>8</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.0 &#177; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>9</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not MT active <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>10</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.7 &#177; 4.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">157</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>11</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not MT active <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>12</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">125 &#177; 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>13</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.3 &#177; 8.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">118</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>14</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not MT active <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CA-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.4 &#177; 0.6 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Results previously published [<xref rid="B26-molecules-27-00321" ref-type="bibr">26</xref>]; <sup>b</sup> Results previously published [<xref rid="B25-molecules-27-00321" ref-type="bibr">25</xref>]; <sup>c</sup> At a 10 &#181;M concentration.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-27-00321-t003" orientation="portrait"><object-id pub-id-type="pii">molecules-27-00321-t003_Table 3</object-id><label>Table 3</label><caption><p>Inhibition of tubulin assembly and colchicine binding.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of Tubulin Assembly <break/>IC<sub>50</sub> &#177; SD (&#956;M)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of Colchicine Binding <break/>(% inhibition &#177; SD) at 5 &#956;M</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>1</bold>
<sup>a</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4 &#177; 0.007</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84 &#177; 0.50</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>2</bold>
<sup>b</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3 &#177; 0.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.0 &#177; 5.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>3</bold>
<sup>b</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3 &#177; 0.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.0 &#177; 4.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82 &#177; 0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.0 &#177; 1.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>5</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.49 &#177; 0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.0 &#177; 2.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.49 &#177; 0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.0 &#177; 0.40</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>8</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56 &#177; 0.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.0 &#177; 0.40 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>10</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.54 &#177; 0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.0 &#177; 0.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CA-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0 &#177; 0.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.0 &#177; 0.20</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Results previously published [<xref rid="B26-molecules-27-00321" ref-type="bibr">26</xref>]; <sup>b</sup> Results previously published [<xref rid="B25-molecules-27-00321" ref-type="bibr">25</xref>].</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-27-00321-t004" orientation="portrait"><object-id pub-id-type="pii">molecules-27-00321-t004_Table 4</object-id><label>Table 4</label><caption><p>Effect on &#946;III-Tubulin and Pgp-Mediated Cancer Cell Resistance.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> &#177; SD in HeLa (nM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> &#177; SD in HeLa WT<italic toggle="yes">&#946;</italic>3 (nM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Rr Value (WT <italic toggle="yes">&#946;</italic>3/HeLa)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> &#177; SD in SK-OV-3 Cells (nM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> &#177; SD in SK-OV-3 MDR1-M6/6 Cells (nM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Rr Value (M6/6/SK-OV-3)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>1</bold>
<sup>a</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.3 &#177; 2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.4 &#177; 3.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.6 &#177; 1.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.4 &#177; 5.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>2</bold>
<sup>b</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">118 &#177; 13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.4 &#177; 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">156 &#177; 16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">160 &#177; 15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>3</bold>
<sup>b</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">142 &#177; 8.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.5 &#177; 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">173 &#177; 8.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">224 &#177; 21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.5 &#177; 1.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.6 &#177; 1.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.8 &#177; 1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.5 &#177; 0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>5</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.3 &#177; 4.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.1 &#177; 4.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.8 &#177; 5.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74.1 &#177; 11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">123 &#177; 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80.3 &#177; 6.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.5 &#177; 3.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91.7 &#177; 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.2 &#177; 8.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.0 &#177; 3.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.0 &#177; 6.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.1 &#177; 7.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>8</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.9 &#177; 8.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.3 &#177; 5.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.7 &#177; 1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.5 &#177; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>10</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">146 &#177; 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108 &#177; 8.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">136 &#177; 15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">209 &#177; 40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>12</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">191 &#177; 8.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">203 &#177; 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">178 &#177; 1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">223 &#177; 9.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>13</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">170 &#177; 34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">139 &#177; 20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">142 &#177; 22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">143 &#177; 244</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.8 &#177; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.0 &#177; 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.0 &#177; 0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1200 &#177; 58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">240</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CA-4 <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.3 &#177; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.3 &#177; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5 &#177; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.2 &#177; 1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Results previously published [<xref rid="B26-molecules-27-00321" ref-type="bibr">26</xref>], <sup>b</sup> Results previously published [<xref rid="B25-molecules-27-00321" ref-type="bibr">25</xref>], <sup>c</sup> Results previously published [<xref rid="B25-molecules-27-00321" ref-type="bibr">25</xref>], WT= Wild type, M6/6 = SK-OV-3 MDR1- M6/6.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-27-00321-t005" orientation="portrait"><object-id pub-id-type="pii">molecules-27-00321-t005_Table 5</object-id><label>Table 5</label><caption><p>Human Cancer Cell Growth Inhibitory Activity GI<sub>50</sub> (nM) of <bold>4</bold> in the NCI-60 Cell Line Panel.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Panel/Cell Line</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GI<sub>50</sub> (nM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Panel/Cell Line</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GI<sub>50</sub> (nM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Panel/Cell Line</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GI<sub>50</sub> (nM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Panel/Cell Line</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GI<sub>50</sub> (nM)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Renal Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCRF-CEM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COLO 205</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LOX IMVI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">786-0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.44</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HL-60(TB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCC-2998</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MALME-3M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A498</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K-562</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT-116</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACHN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.23</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MOLT-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT-15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-435</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAKI-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.84</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RPMI-8226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HT29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RXF 393</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.65</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KM12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SN12C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.36</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549/ATCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SW-620</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-MEL-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TK-10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.21</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EKVX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CNS Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UACC-257</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UO-31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.82</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP-62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-268</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UACC-62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP-92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-295</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCF7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-539</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IGROVI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-231/ATCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.93</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNB-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS 578T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.46</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H322M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNB-75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BT-549</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.48</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H460</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U251</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-468</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.05</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H522</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prostate Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OVCAR-8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PC-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.67 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI/ADR-RES</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DU-145</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK-OV-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap></sec></back></article></pmc-articleset>